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ABSTRACT
The dopamine transporter (DAT) is a presynaptic membrane
phosphoprotein that terminates dopaminergic synaptic transmission by clearing
dopamine (DA) back into presynaptic neuron by a reuptake process. DAT is also
a molecular target for psychostimulants such as cocaine, amphetamine (AMPH)
and methamphetamine (METH) that increase DA synaptic levels either by
blocking reuptake or by inducing DA efflux. DAT phosphorylation and transport
down regulation are best demonstrated with the treatment of Protein kinase C
(PKC) activators such as (phorbol 12-myristate 13- acetate) PMA. Serine(s) and
threonine(s) are known to be involved in DAT phosphorylation.
Pretreatment with psychostimulant substrates such as AMPH and METH
have been shown to regulate DAT phosphorylation and DA transport activity.
Here we have examined the effects of DA, cocaine and various other
psychoactive transport blockers on DAT phosphorylation and regulation in rDAT
expressing LLC-PKi cells by using 32P04 metabolic labeling and [3H] DA uptake
assays. Pretreatment with cocaine or methylphenidate (MPH) had no effect on
basal or PMA stimulated DAT phosphorylation and DA transport. GBR 12909
suppressed PMA-induced DAT phosphorylation and internalization. Treatment
with DA did not affect DAT phosphorylation while inducing PKC mediated DA
transport down regulation. These results provide information on the potential for
endogenous and psychoactive compounds to modulate DAT
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CHAPTER I
INTRODUCTION
Synaptic Transmission
Billions of neurons in the human nervous system communicate with each
other to orchestrate complex behaviors, perceptions, reflexes, instincts,
emotions, thinking and learning. Mostly, the communication occurs between
neurons or between neuron and muscle through specialized junctions called
“synapses” and the process by which one neuron communicates with other
neuron is called “synaptic transmission”.
Synaptic transmission is initiated with a wave of depolarization along the
axon called an action potential. Because the action potential cannot be
propagated directly between the cells that are separated by a synaptic cleft,
chemical messengers “neurotransmitters” are employed to communicate
between one cell and the next. The synaptic transmission process includes the
following events, namely the fusion of neurotransmitter containing synaptic
vesicles with presynaptic plasma membrane, release of neurotransmitters into
synaptic cleft, activation of post synaptic receptors and sequestration of released
neurotransmitters.
Neurotransmitters are synthesized in the neuronal cell body and packaged
into synaptic vesicles. The packaged vesicles are vectorially directed towards the
presynaptic membrane and docked to specific regions of membrane called
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active zones. The docked vesicle undergoes maturation by a process called
priming that enables the membrane fusion of vesicles. When an action potential
reaches the nerve terminal, it induces the opening of voltage gated Ca2*
channels which leads to rapid influx of Ca2+ into the cell. This leads to a spike in
local intracellular Ca2+ levels and triggers the membrane fusion of synaptic
vesicles and results in exocytosis of neurotransmitters into the synaptic space [13]The neurotransmitters released into synapse are readily available for the
activation of the postsynaptic receptors that further stimulate depolarization in the
postsynaptic neuron. In order to terminate synaptic transmission effectively, the
released neurotransmitters must be degraded by specific enzymes or re
accumulated into the presynaptic neurons or glial cells through specific
membrane transporter proteins.
The Dopaminergic System
The dopaminergic system refers to the dopaminergic neurons that
synthesize and release the neurotransmitter dopamine (DA). The dopaminergic
system is involved in cognition, motor activity, and reward. Disorders associated
with DA are attention deficit hyperactivity disorder (ADHD), motor/movement
disorders such as Parkinson disease, addiction, schizophrenia, paranoia and
autism [4]. In brain, dopaminergic neurons primarily originate from three areas
that include the ventral tegmental area (VTA) of the mid brain, the substantia
nigra pars compacta and the arcuate nucleus of the hypothalamus.

Figure 1. The Dopaminergic System. Dopaminergic system representing the
dopaminergic neurons that primarily originate from the ventral tegmental area
(VTA) of mid brain, the substantia nigra pars compacta and the arcuate nucleus
of the hypothalamus. Neurons from these areas project axons to many areas of
brain such as the cerebral cortex especially to frontal lobes, the striatum, and the
median eminence or infundibular region.

Nigrostriatal pathway

Mesolimbic pathway

Prefrontal
cortex

Striatum

Mesocortical pathway
Substantia
nigra

Tuberoinfundibular pathway
Mesobasal
hypothalmus
Ventral
tegmental area

Image courtesy of Benjamin Cummings/ Pearson Education: Human physiology,
3rd edition, Figure 9.19c, with permission
Figure 1. The Dopaminergic System
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Neurons from these areas project axons to many areas of brain with four
neural pathways namely the Mesocortical, Mesoiimbic, Nigrostriatal, and
Tuberoinfundibular pathways (Figure 1). The mesocortical pathway originates
from the VTA and spreads to the frontal lobes of cerebrum and is implicated ,n
motivation and emotional response. The mesoiimbic pathway links the VTA and
nucleus accumbens that is located in the striatum and is associated with reward
circuits. Therefore, this pathway has been implicated in drug addiction process
[5], The nigrostriatal pathway connects the substantia nigra with the striatum and
is particularly important in motor control. The degeneration of these neurons
leads to Parkinson disease. The tuberoinfundibular pathway contains neurons of
the arcuate nucleus and projects into the median eminence (the 'infundibular
region’). This pathway is known to regulate the secretion of prolactin from the
anterior pituitary gland.
Metabolism of Dopamine
Dopamine, norepinephrine (NE) and epinephrine belong to the group of
catecholamine neurotransmitters. Catecholamines act as neuromodulators
and/or hormones in the central nervous system (CNS). NE is a biologically
derived product of DA and acts as a precursor for epinephrine biosynthesis.
Tyrosine, a precursor for biosynthesis of all catecholamines, is converted to 3, 4dihydroxy-L-phenylalanine (L-DOPA) by a rate limiting enzyme tyrosine
hydroxylase (TH). TH is present in ail catecholamine synthesizing cells and
catalyzes the addition of a hydroxyl group to the meta-position of tyrosine. The

conversion of L-DOPA to DA is the final step of the catecholamine biosynthetic
pathway in dopaminergic neurons, which is catalyzed by DOPA decarboxylase.
DA is synthesized in the cytosol and is present in low concentrations (pM
range). The uptake of monoamines from the cytoplasm into vesicles is mediated
by vesicular monoamine transporter 2 (VMAT2) along with an ATPase-generated
proton gradient. Additionally, this mechanism concentrates intra-vesicular DA up
to 0.5 M. During synaptic transmission, these vesicles release DA into the
synaptic cleft by exocytosis. Termination cf DA synaptic transmission occurs
through rapid reuptake of DA by a membrane bound carrier or transporter
protein, the dopamine transporter (DAT), present on presynaptic membrane. DA
is taken up into the cytosol and transported back into vesicles via VMAT2 for
another round of exocytosis. During this process, some of the cytosoiically
located free DA molecules are catabolized into 4-Hydroxy-3-methoxyphenylacetic acid or homovanillic acid (HVA) by monoamine oxidase (htAO) and
catechol-O-methyltransferase (COMT). Accumulation of HVA in the striatum is
used as a biomarker to assess the progression of PD.
The reuptake of catecholamines was first described by Axelrod et al
( iwwd) with usage of radiolabeled NE [6]. Synpatosomal accumulation of
radiolabeled NE in the presence of catecholamine catabolic blockers, has
demonstrated the first evidence of catecholamine uptake [7]. In contrast, cocaine
treatment decreased the accumulation of radioactive NE suggesting that this
transport is carrier mediated event [8]. Subsequent experiments have shown that
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the uptake process is Ua* and Cl -dependent and exhibits Michaelis-Menten
saturation kinetics [6, 9].
Cloning of DAT
Until 1990, synaptosomal preparations and/or Xenopus laevis oocytes
injected with substantia nigra mRNA were used to study DAT or other
neurotransmitter transporters [10J. Kanner et al (1990) were the first to done the
gamma-amino butyric acid (GABA) neurotransmitter transporter 1 (GAT1/SLCA1)
using the purified protein sequence and characterize GABA transport by
expressing GAT1 in a heterologous system [11] The adoption of expression
cloning strategy is expedited the cloning and characterization of the
norepinephrine transporter (NET/SLCA2) [12], DAT (SLCA3) [13, 14] and
serotonin transporter (SERT/ SLCA4) [15]. Based on cDNA sequence homology;
DAT belongs to a Na* and CT - dependent solute carrier (SLC 6) family of
plasma membrane neurotransmitter transporters that also includes GAT', NET,
SERT, and the glycine transporter (GLYT) [16] The SLC6 family of transporters
requires Na* in order to generate the electrochemical gradient and to drive
transport of the neurotransmitters against their concentration gradient [17, 18]
DAT Structure
DAT contains 619 amino acids in rat (rDAT) and 620 amino acids in
human (hDAT). The predicted topology indicated that DAT has twelve
transmembrane domains (TMs) that are connected by intracellular (ILs) and
extracellular loops (ELs) and N- and C-cytosolic tail domains (Figure 2). TMs are
presumed to form a pore for substrate translocation. A large extracellular loop 2
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Figure 2. Schematic Diagram of rDAT. This is a predicted topological
representation of rat DAT structure. The structure of rDAT contains twelve TMs,
and cytosolically located N- and C-terminai ta.l domains. A large extracellular
loop is present between TMs 3 and 4 with four glycosylation sites.
Multiple serines (S), threonines (T) and tyrosines (Y) that may be involved in
phosphorylation are shown in red, green and yellow respectively. The region
highlighted with blue on the N-terminal cytosolic tail represents epitope 16 that
was used for preparation of antibodies.

&

Figure 2. Schematic Diagram of rDAT.
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(EL2) connects TMs 3 and 4 and its glycosyfation is required for proper surface
expression and DA transport activity [19]. fn addition to glycosyiation, DAT is also
known to undergo a variety of post translational modifications including
phosphorylation and ubiquitylation on cytosolic tail domains. The N- and Cterminai tail domains and ILs are rich with multiple potential phosphorylation sites
[20],

Molecular Properties of DAT
A large body of evidence concluded that neurotransmitter transporters
terminate synaptic transmission. DA uptake was demonstrated 35 years ago [8],
but the development of specific radiolabeled ligands in 1980’s [26, 27] and
cloning of DAT in 1990's have expedited the current understanding of DAT
physiology.
DAT transports the substrate DA inwardly against a concentration gradient
using the driving force of Na+ across the membrane. Two sodium ions and one
chloride ion are co-transported along with one molecule of DA and make this
process electrogenic [21]. The mechanism of DA translocation is proposed to
occur through a cascade of conformational changes in DAT that allows the
binding site to be alternatively accessible to extracellular or intracellular sides of
the membrane [17]. This process keeps the DAT in an open conformation
towards the extracellular side and in a closed conformation on the intracellular
side. Binding of DA and ions to DAT induces a conformational change that
results in a closed state on extracellular side and an open state on intracellular
side. Following the release of DA and ions into the cytosol, DAT resets to an
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open conformation on the extracellular side for a new transport cycle. In addition
to forward transport, DAT can transport DA in the reverse direction (i.e., into the
extracellular space) under some circumstances, such as following exposure to
amphetamines [22],
Lack of three dimensional structure of DAT has limited the information
about binding sites of DA, Na+, Cl' and transport blockers and conformations
attained during substrate translocation and binding of transport blockers.
Recently, Gouaux et al (2005) have crystallized and elucidated the structure of a
ieucine transporter derived from Aquifex aeolicus (Leu TAa) that shares ~ 20%
sequence identity with DAT and other SLC6 family transporters [23]. In spite of
low sequence identity with DAT and other neurotransmitter transporters, a high
resolution Leu TAa crystal structure has advanced the understanding of the
structural basis of the transport mechanism. TMs1 and 5 and TMs 6 and10 in
Leu TAa crystal structure exist as two superimposable internal structural repeats
by rotation in the plane of membrane. These superimposable internal repeats
interact with one another to form a permeation pathway. During this process, TM
1 and TM 6 form the binding sites for substrate and Na+.
Many electrophysiological studies have revealed that DAT can mediate
macroscopic ionic currents, which are not stoichiometrically linked to substrate
movement [21, 24-26], and is a common property of ion channels. The transport
current is elicited by DA and other substrates, which can be blocked by non
substrate blockers. Additionally, a tonic leak conductance generates steady-state
current, which is not coupled by substrates, but can be blocked by substrates
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and cocaine like drugs [25, 27]. Therefore physiological properties of DAT
include the termination of neurotransmission by rapid reuptake of extracellular
DA, reverse transport, and channel like properties [28].
Oligomerization of DAT
Experiments involving chemical crosslinking, mutagenesis,
coimmunoprecipitation, and fluorescence resonance energy transfer (FRET)
have demonstrated that DATs exist as oligomeric complexes [29-31]. The
mutation of cysteine-243 in TM 4 and cysteine-306 in TM 6 results in decreased
crosslinking ability of DAT suggesting that the interface of TM 4 and 6 may be
involved in DAT oligomerization [31, 32]. The co-expression of non-functional
cytosolic tail DAT mutant constructs with Wt DAT decreases the transport activity
and surface expression of DAT. This dominant negative effect on transport
activity was rescued by mutating a leucine zipper motif present in TM 2. These
results indicate that the leucine zipper motif is important for oligomerization of
DAT, and oligomerization is necessary for DAT surface expression and DA
transport activity [29].
The substrate bound crystal structure of Leu T negates the possibility of
formation of TM 4 and TM 6 interface during oligomerization, because these
domains are deeply buried in this conformation. However, this interface may exist
in conformations where DAT is not bound with substrates or blockers. Treatment
with the substrates DA or AMPH reduced the cross linking ability of surface DAT
demonstrating that substrates dissociate oligomerization of DAT [33].
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Pharmacology of DAT
Dopamine is a neurochemical mediator of critical functions such as
movement, emotion and reward. Abnormal levels of DA are associated with a
variety of pathological conditions and pharmacological treatments. DAT is a very
important target for pharmacological or recreational psychoactive drugs (Figure
3).
Psychostimulant Substrates
The term amphetamines represents both AMPH and methamphetamine
(METH) which are potent psychomotor stimulants originally developed to treat
asthma, sleep disorders (narcolepsy) and hyperactivity. They stimulate the CNS
and sympathetic division of the peripheral nervous system and increase the
synaptic levels of DA and NE. The reinforcing properties produced by
amphetamines are linked to the elevation of extracellular DA levels suggesting
that AMPH or its derivatives promote nonvesicular release of DA into the
synapse through DAT [34-36], AMPH is a non physiological substrate for DAT
and chemically acts as a lipophilic weak base. The entry of AMPH into synaptic
vesicles leads to collapse of the vesicular pH gradients followed by redistribution
of DA from synaptic vesicle into the cytosol [37], METH has been shown to
produce faster and longer-lasting effects than AMPH in comparable
concentrations possibly due to its higher hydrophobicity.
AMPH induced DA efflux is thought to occur by an exchange diffusion
model [38], This model is based on an alternating access model of DA uptake. In
the alternating access model, binding of cargo (DA, N a\ and Cl ) to an
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extracellularly oriented transporter induces a conformational rearrangement to an
intracellularly oriented transporter. This leads to release of cargo into the cytosol,
thereby completing the transport process. DA efflux induced by AMPH is
believed to result from the ability of AMPH to reverse this inward transport
process, in that the inward transport of AMPH by DAT increases the number of
“inward-facing” transporter binding sites and thereby increases the rate of
outward transport of DA through an exchange process [39]. Therefore this
process increases extracellular DA levels that in turn enhances the synaptic
activity of postsynaptic receptors and eventually leads to positive reinforcement.
For example, Khoshbouei et at. (2004) [40] recently reported that DAT N-terminal
phosphorylation plays a critical role in AMPH-induced DA efflux but not in DA
uptake. Theserdata suggest that AMPH-induced DA efflux mediated by the
reversal of DAT is more complex than a simple exchange process [28].
Neurotoxins
In addition to psychostimulant drugs, DAT is also a target for neurotoxins
that exert degenerative effects on DA systems such as the pathogenesis of
Parkinson’s disease. Neurotoxins such as 6-bydroxydopamine (6-OHDA) and 1methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) chemically damage
dopaminergic neurons in vivo [41, 42] and have been shown to produce
Parkinson disease symptoms in animal models [43]. 6-OHDA is a hydroxylated
analogue of natural substrate DA. MPTP is a contaminant produced during the
synthesis of MPPP (1-methyl-4-phenyl-4-propionoxypiperidine), an opioid
analgesic drug. Following entry into living organism, MPTP will be converted into
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neurotoxic metabolite t-methyl-4-phenylpyridinium (MPP+) that produces toxic
effects on cell. So MPP+ and 6-OHDA are selectively accumulated in
dopaminergic neurons through DAT and increase the formation of reactive
oxygen species. Reactive oxygen species inhibit the function of mitochondrial
complex I that further leads to mitochondrial dysfunction and cell death [44, 45].
Uptake Blockers
Cocaine
Cocaine is a psychostimulant drug and it produces a wide range of
emotional experiences and reinforcement properties in users. Cocaine occurs
naturally as an alkaloid in the leaves of coca (Erythroxylon coca) and has been
federally classified as schedule II controlled substance drug due to its
exceptional potential for abuse. Although cocaine possession, cultivation, and
distribution is illegal for non-medicinal and non-government sanctioned purposes,
it has been used world wide in many cultural, social and personal settings.
Cocaine is a powerful reinforcer and this property is believed to contribute
to cocaine abuse and dependence [46, 47]. The reinforcement properties of
cocaine have been demonstrated in humans and animal models by self
administration and other behavioral techniques. Various neurochemical and
neuroanatomical studies have shown that dopaminergic mesolimbocortical
neurons are important for the reinforcing properties of cocaine [48], Ligand
binding studies have identified the DAT as one of the major cocaine receptors in
brain [47], The inhibitory potencies of cocaine and related compounds for DAT
have shown a correlation with behavioral potencies obtained from drug
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Figure 3. DAT Substrates, Neurotoxins and Psychostimulant Blockers.
Representative chemical structures of (A) Psychostimulant Substrates (B)
Neurotoxins (C) Psychostimulant blockers and (D) Psychoactive Therapeutic
Agents.
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Figure 3. (A) DAT substrates, (B) Neurotoxins and (C, D) Psychostimulant
Blockers.
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reinforcement studies [47]. Additionally, microdialysis studies have shown that
cocaine treatment increases extracellular DA levels in the limbic area
reconfirming that DAT is major site of action for cocaine (reviewed in [46]).
GBR 12909
GBR 12909 (1-{2-[bis~(4-fIuorophenyl) methoxy] ethyl]-4-(3-phenylpropyl)
piperazine) is a noncompetitive, potent and selective inhibitor of DA uptake [49].
This compound was developed as a therapeutic for drug abuse to produce
minimal or no euphoria, which may reduce abuse potential and dependence.
GBR 12909 has been demonstrated to possess a different pharmacological and
behavioral profile compared to cocaine [50]. When compared to cocaine, GBR
12909 has much higher affinity for DAT [51]. The ora! administration of GBR
12909 in normal human volunteers has shown a non stimulant profile that is
different from the cocaine induced profile [52]. These properties have promoted
GBR 12909 for preclinical and phase I clinical trials as a potential therapeutic
agent for cocaine abuse [53, 54],
Mazindol
Mazindol is a tricyclic compound and has been used as an appetite
suppressant for treatment of exogenous or short term obesity and as an orphan
drug for the treatment of Duchenne muscular dystrophy. It stimulates the CNS to
increase heart rate and blood pressure, and decrease appetite. The mechanism
of mazindol action is not known, however it act as a reuptake inhibitor for
monoamine transmitters [55], Mazindol was found to be non-addictive and it did
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not produce euphoria in clinical trials [56] But in monkeys, a subset of ail tested
had shown the self-administration behavior [57]
Methylphenidate
Methylphenidate (WPH) is a generic therapeutic stimulant prescribed for
ADHD. It is also used for daytime drowsiness symptoms of rarcotepsy and
chronic fatigue syndrome. MPH acts on the CNS to reduce impulsive behavior
and induce attention on work and other tasks [58]. The mode of MPH action in
ADHD diagnosed individuals is not well understood. MPH blocks the transport
activity of DAT and NET and increases synaptic dopamine levels that in turn
stimulate the under activated brain regions [59].
Regulation of DA Transport and DAT Phosphorylation
The cloning of DAT and identification uf the crystal structure for a DAT
homologue has provided the basis for current understanding of DAT structure
and function. The cloning of DAT made it possible to characterize DA transport
activity, DA efflux and mechanisms that regulate uptake or efflux. DAT functions
are regulated by protein kinases, protein phosphatases, and protein- protein
interactions.
Protein Kinases
The presence of multiple potential phosphorylation sites on cvtosolic tails
and ILs of DAT suggested that protein kinases can regulate DAT function (Figure
4). DA transport activity can be regulated by multiple signaling pathways, protein
kinase A (PKA), protein kinase C (PKC), protein kinase G (PKG),
calcium/calmoduiin dependent protein kinase (CaMK II) and mitogen activated
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Figure 4. Cytosolic Tail Domains of DAT Showing the Putative Phosphorylation
Sites for Various Protein Kinases (A) N*terminal cytosolic tail domain (B) Cterminal cytosolic tail domain of DAT showing enlarged S/T sites. Some of the
S/T sites are enclosed in boxes that represent the consensus recognition-motives
for various protein kinases. Color of stars on the top of the box denotes the
kinase specificity. (PKC = Red, PKA = Blue, CaMKtt = Black, CKII = yellow,
ERK1/2 = Green)
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protein kinases (MAPK’s) [21, 60-62]. The down-regulation of transport activity
has been well demonstrated by PKC activators in both striatal synaptosomes and
heterologously expressing cells. Activation of PKC leads to decreased transport
Vmax with no change in Kmfor DA. This decreased DA transport has been
demonstrated to occur through trafficking dependent and independent
mechanisms. The trafficking dependent mechanism involves the dynamindependent and clathrin-mediated endocytosis of DAT following the treatment with
PKC activators leading to decreased surface expression. DATs present in
detergent-resistant membrane raft populations are regulated by cholesterol
dependent non-trafficking regulatory mechanisms. These studies suggest that
multiple regulatory mechanisms are involved in regulation of DA transport
activity.
Vaughan et al (1997) identified DAT phosphorylation both in rat striatum
[63] and in cell lines [64] and this identification shed light on the possible role of
phosphorylation in the regulation of DA transport. In vivo 32P metabolic labeling
followed by phosphoamino acid analysis of DAT has demonstrated that serine(s)
(Ser) and threonine(s) (Thr) are involved in both basal and PMA stimulated DAT
phosphorylation [65]. The combination of in vitro proteolysis followed by
phospho-peptide mapping demonstrated an N-terminai cluster of Ser(s) as the
major site(s) of DAT phosphorylation. The truncation of the first 21 amino acids in
DAT (A 21) leads to the loss of DAT phosphorylation while retaining PMA
induced DA transport down regulation demonstrating that N-terminal
phosphorylation is not required for down-regulation of DA transport activity [6 6 ].

Various studies have shown roles for other protein kinases including PKA,
CaMK II and the extracellular signal regulated kinase (ERK) family of MAPKs on
DAT phosphorylation and regulation, but far less is known about their role in DAT
properties compared to PKC. Treatment of cells with PKA activators such as 8 bromo-cAMP [67] and forskolin did not affect DA transport activity and DAT
phosphorylation [63]. Although chemically synthesized N-terminus of DAT
comprising of 1-27 aminoacid peptide has been shown act as in vitro substrate
for CaMKII, phosphorylation sites involved in this process are not known [6 8 ]. In
vivo pharmacological studies have shown that CaMKII regulates the DA transport
activity [67]. In vitro studies have Acute treatment of synaptosomes or cells with
phosphatidylinositol (PI) 3-kinase (PI3 Kinase) inhibitor decreased [3 H]DA uptake
and DAT surface expression, presenting a role of PI3 kinase in regulation of DAT
function [69].
Moron et at (2003) have shown that the blockade of ERK activation using
MAPK kinase (MEK) inhibitors U0126 or PD98059 resulted in decreased [3 H] DA
transport Vmax and surface expression of DAT [70]. Further, the transient
transfection of a constitutively active MEK mutant increased DA uptake.
Collectively, these results suggest that the activation of ERKs regulate DAT
surface expression and DA transport activity. Interestingly, MEK inhibitors
suppressed basal DAT phosphorylation without affecting PMA stimulated
phosphorylation [71], showing that ERK regulates the constitutive
phosphorylation of DAT.
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Protein Phosphatases
In addition to protein kinases, protein phosphatases are aiso known to
affect DA transport and DAT phosphorylation. The treatment of synaptoscmes
with pharmacological protein phosphatase inhibitor, okadaic acid tOA) increased
DAT phosphorylation and decreased DA transport activity [63]. Treatment of
striatal homogenates with punfied protein phosphatases

1

(PP1) and 2A tPP2A)

leads to dephosphorylation of DATs [72]. These studies have suggested that
DAT undergoes dephosphorylation and phosphorylation in native conditions.
However the underlying mechanisms involved in this process are not known
DA T-Protein Interactions
Increasing evidence suggests that DATs are regulated through proteinprotein interactions. Over the past few years, different proteins have been ~
identified that interact with cytosolic domains of DAT These DAT- protein
interactions were shown to play a role in trafficking, subcellular distribution,
compartmentalizaiton of DAT, and DA forward and reverse transport activity. The
list of interactive proteins include receptor for activated C kinase-1 (RACK1),
syntaxin [73], CaMKII [6 8 ]. PKC-(3 [74] and protein phosphatase PP2A [75]
Various methods were followed to identify these interacting proteins such as
yeast two-hybrid (Y2H) system, GST pull downs, and co-immunoprecipitation.
Interestingly, many of these proteins were also shown to interact with other
members of SLC6 transporter family [76-79],
The C-terminal tail of DAT acts as binding partner for CaMKII and this
binding interaction has been shown to play a role in AMPH-induced DA efflux
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through N-terminai DAT phosphorylation [6 8 ]. The amino terminus of DAT has
been reported to interact with a PKC substrate RACK1 and syntaxin, a member
of the soluble N-ethylmaleimide-sensitive factor attachment protein receptor
(SNARE) family [73], The functional analysis of RACK1 binding has yet to be
ascertained. Syntaxin is also shown to interact with both GAT1 and NET and
negatively regulate their transport activities [78, 80]. Based on the shared protein
sequence homology with NET, it can be presumed that DAT-syntaxin interaction
may exert similar effects on DAT functional properties. Based on involvement of
PKC in DAT functional and other properties, it can be assumed that PKC may
interact with DAT. Recently; PKC-[3 has been shown to interact with DAT and
regulate the amphetamine induced DA efflux [74],
In addition to protein kinases, protein phosphatases were also shown to
regulate the DAT phosphorylation and regulation. Co-immunoprecipitation
studies have shown that DAT forms a protein complex with protein phosphatase
2Ac [75] and this result suggests that protein phosphatases may regulate DAT
phosphorylation or function via protein-protein interaction.
Effects of Substrates and DA Efflux
The physiological substrate DA and psychostimulant substrates AMPH
and METH induce DA transport down regulation and internalization of DAT in
both synaptosomes and cell lines [81-83]. In addition to transport down
regulation, pretreatment with AMPH or METH, but not DA induced DA efflux
through DAT. Inclusion of bisindolylmaleimide (BIM), a general PKC inhibitor [84,
85] or a PKC-P specific inhibitor LY379196 [74], blocked the AMPH- or METH-
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induced transport down regulation and DA efflux suggesting that AMPH- or
METH-induced down regulation or DA efflux occurs via PKC dependent
mechanisms. Additionally, the treatment of cells or striatal tissue with AMPH or
METH increased DAT phosphorylation.
Interestingly, the truncation of the first 22 amino acids on the DAT Nterminal tail (A 22) abolished METH induced DA efflux and DAT phosphorylation
while not affecting the functional down regulation of DAT [85]. Additionally, the
simultaneous mutation of five Ser—►alanine (Ala) (S2, S4, S7, S12, and S13) on
the N-terminal tail of DAT produced an 3/A background mutant that displayed
impaired DA efflux similar to A 22 mutant [40]. In contrast, the individual mutation
of A—►aspartate (Asp) on the S/A background mutant at 7 or 12 restored the
significant amount of wild type DA efflux. These results suggest that N-terminal
phosphorylation possibly at S7 or S12 is essential for AMPH-induced DA efflux.
CaMKII has been shown to induce DA efflux [8 6 ]. The combination of
biochemical and eiectrophysiological studies has shown that the binding of
CaMKII to the C-terminus of DAT is important for regulation of AMPH-induced
DA efflux [6 8 ],
In most of these studies, psychoactive drugs were examined in isolation
for their effects on DAT phosphorylation or regulation, and less has been done to
examine drug effects in combination with PKC activators to investigate potential
biochemical interactions of the processes.
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Effects of Uptake Blockers
Compounds used to treat neuroiogical disorders or that lead to drug
addiction including cocaine, 2|3-carbomethoxy-3f3-(4-fluorophenyl) tropane (PCFT), GBR 12909, mazindol, and MPH can bind to DAT and inhibit substrate
transport. Various studies have examined the effects of cocaine on DAT
regulation and showed conflicting results. Pretreatment of cells with cocaine had
no effect on [3 H] DA uptake or surface expression [82, 83] while others have
reported increased DAT surface expression and transport activity [87]. In
contrast to psychostimulant substrates, cocaine has been reported to suppress
PMA-induced DAT phosphorylation [8 8 ].
The present studies were focused on examining the effects of DA and
~ uptake blockers such as cocaine, 2p-carbomethoxy-3(3-(4-fluorop'henyl) tropane
((3-CFT), GBR 12909, mazindol, and MPH on PKC dependent and independent
properties of DAT using rDAT expressing LLC-PK! cells. These studies are
expected to identify the effects of drugs on DAT phosphorylation and DA
transport activity, which potentially may be involved in differential behavioral
responses that are regulated by DAT phosphorylation and drug pretreatments.
These studies also compare the previously known effects of other monoamine
transmitters on cognate transporter regulation or phosphorylation.
Although PMA treatment increased N-terminal DAT phosphorylation, it is
not known if PKC is directly involved in this process. Additionally, the N-terminal
tail of DAT contains multiple phosphorylation sites for various protein kinases, but
it is not known if these protein kinases regulate the N-terminal phosphorylation.
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Previous studies have shown that phosphorylation of DAT occurs on Ser(s) and
Thr(s) in vivo\ however, the sites involved in this process are not known.
Therefore, the other section of present studies is designed to investigate the
ability of serine/threonine protein kinases to phosphorylate a recombinantly
expressed cytosolic N-terminal tail of DAT that may represent the N-terminus of
in vivo DAT. The results of these studies will help in identifying the sites, protein
kinases or protein phosphatases involved in N-terminal phosphorylation of DAT.
Further, the correlation of obtained results with known in vivo findings will
increase the understanding of DAT phosphorylation and its role in DAT function.
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CHAPTER I!
MATERIALS AND METHODS
Materials
Animals
Male Sprague Dawley rats (175-300 grams) were obtained from Charles
River Laboratories (Wilmington, MA) and were maintained in compliance with the
guidelines established by the University of North Dakota Institutional Animal Care
and Use committee and the National Institutes of Health.
Reagents
Radiolabeled inorganic phosphate (H3 [3 2 P]04) and [y-32 P] ATP (7000
Ci/mmol) were purchased from MP Biomedicals (Irvine, CA). [3 H] dopamine
(45Ci/mmol), Protein A sepharose beads, High and Low range Rainbow
molecular weight markers were obtained from GE Healthcare Life Sciences
(Piscatway, NJ). (-)-Cocaine, 23-carbomethoxy-3p-(4-fluorophenyl) tropane (3CFT), mazindol, methylphenidate (MPH), GBR 12909, dopamine and sulpride
were from Sigma-Aldrich (St.Louis, MO). PMA, Bisindolylmaleimide I (BIM), OA,
OAG, PKC classical isoforms (a, (31, 311, and y) (Specific activity for PKC
isoforms: One unit is defined as the amount of enzyme that will transfer 1.0 n mol
of phosphate to histone H1 per minute at 30°C, pH 7.4), PKA, PKG, CaMK II,
ERK1/2, p38 kinase, JNK, GSK-33, Akt, Cdk-5 (Specific activity: One unit is
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defined as the amount of enzyme that will transfer

1 .0

p mol of phosphate to the

synthetic substrate GRTGRRNSI per minute at 30aC, pH 7.4), protein
phosphatases (PP1, PP2A, and PP2B) (Specific activity for PP1 and PP2A: One
unit is defined as the amount of enzyme that will hydrolyze 1.0 n mol of [3 2 P]
inorganic phosphate from
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P-Iabeled phosphorylase per min; specific activity for

PP2B: One unit is defined as the amount of enzyme that will release 1.0 p mol of
phosphate from the Rll phosphopeptide substrate per min at 30°C) and
Endoproteinase Asp-N were from Calbiochem/EMD Biosciences (La Jolla, CA).
EZ-Link Sulfo-NHS-LC-Biotin and Immobilized Neutravidin beads were from
Pierce Biotechnology (Rockford, IL). Complete Mini Protease Inhibitor was
purchased from Roche Applied Science (Indianapolis, IN). IMPACT-CN kit (Intein
expression vectors etc.), all restriction enzymes and modifying enzymes were
obtained from New England Biolabs (Ipswitch, MA). Site directed mutagenesis
QuickChange® kit was purchased from Stratagene (La Jolla, CA). Synthesized
oligonucleotides were from MWG Biotech, Inc (High Point, NC). Isopropyl (3-D-1thiogalactopyranoside (IPTG) and all other fine chemicals were purchased from
Sigma-Aldrich (St.Louis, MO) or Fischer Scientific (Pittsburg, PA).
Equipment
Centrifuges
The Beckman J6 -MI swinging bucket rotor was used to prepare the crosslinked Protein A Sepharose beads and to pellet the cell lines. Beckman Avanti J25, 16.250 and 25.50 rotors were used for harvesting E.coli cells for both protein
and plasmid isolation purposes. Refrigerated Beckman Microfuge R or a bench
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top Microfuge 18 were used for genera! tab procedures and
immunoprecipitations.
Electrophoresis, Electroelution and Dialysis
Bio-Rad Mini-Protean ttl electrophoresis apparatus and Bio-Rad Mini trans
blot electrophoresis transfer cell were used for SDS-PAGE get electrophoresis
and protein transfers, respectively. Gibco/BRL Life Technologies 250 EX power
supply was used to control electrophoresis and protein transfer.
Phosphorylated proteins were electroeluted from gel-slices using Bio-Rad
electroeluter Model 422 containing 3.5 kDa fitter membranes. Electroeluted
proteins or recombinantly expressed proteins were dialyzed using Pierce Slide ALyzer® 10 kDa or 2 kDa Cassettes respectively
TLC electrophoresis
Hunter Thin Layer Peptide Mapping Electrophoresis System, CE (HTLE7002) was used for two dimensional phosphoamino acid analysis
Spectroscopy
A Beckman DU 640 spectrophotometer was used to quantify plasmid DNA
and Molecular Devices Spectra Max 190 plate reader was used to quantify
protein using the Bicinchonic acid (BCA) method. Radioactive incorporation in
phosphorylated protein samples and in dopamine uptake assays was analyzed
using Packard 1900 CA or Beckman LS6500 liquid scintillation counters
Cell Culture, Molecular Biology and Miscellaneous
Mammalian cell lines were maintained in Nuair 2700-30 water-jacketed
CO2 incubator and handled in sterile Nuair Class II type A/B3 laminar flow hood.
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A Mastercycler personal thermal cyder from Eppendorf was used for all
Polymerase Chain Reaction (PCR) experiments. Bio-Rad Gel Dryer Model 583
was used to dry the SDS-PAGE gels
Methods
Metabolic Phosphorylation of DAT
LLC-PKtCells Expressing rDAT
Prior to labeling the rDAT expressing LLC-PKTcells, cells were
preincubated in phosphate free medium for 30 min. HapPJO* was added to a
final concentration of 0.5 mCi/ml and incubated for 2 h at 37®C. Test compounds
were applied to cells for 30 min. PMA treatments to cells were performed as
positive controls in parallel Cells were washed three times with 1 ml of ice cold
sucrose phosphate buffer (S r) consisting of 0.32 M sucrose and 10 mM sodium
phosphate, pH 7.4, and lysed on ice for 15 min with 500 pi RIPA buffer. Lysates
were centrifuged at 20,000 * g for 20 min at 4QC. The resultant supernatant was
again centrifuged at 100,000 * g for 1 h. The supernatant was collected and
immunoprecipitated with DAT specific antibodies. The immunoprecipitates were
separated by SDS-PAGE and phosphorylated DATs were detected by
autoradiography. Equal exposure times were followed for all autoradiographs to
compare and analyze the phosphorylation intensities.
Rat Striatum
Male Sprague-Dawley rats (175-300 g) were decapitated and the striata
were rapidly removed and weighed. The tissue was sliced into 350 pm slices
using a McElvain Tissue Chopper, and equivalent amounts of tissue (4-8 slices)
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were placed into wells of a 12-well culture plate containing oxygenated Krebsbicarbonate buffer (KBB) consisting of 25 mM N3 HCO3 , 125 mM NaClr 5 mM
KCI, 1.5 mM CaCI2, 5 mM Mg504r and 10 mM glucose, pH 7.3. Slices were
preincubated for 30 min at 30°C, with shaking at 105 rpm, followed by exchange
with fresh buffer containing 1 mCi/ml H3 [3 2 P]0 4, and continued incubation with
shaking at 30°C for 90-120 min. Oxygen (95%

0 2

, 5% C 02) was gently blown

across the top of the plate during the incubation, and test compounds were
added for the final 30 min. Test compounds (OA, and OAG) were dissolved at
high concentrations in dimethyl sulfoxide (DMSO) followed by dilution in the
incubation mixture to a final DMSO concentration of 0.1%. At the end of labeling,
tissue slices were transferred to a microcentrifuge tube and centrifuged at 4°C at
800 x g for 4 min. The supernatant fractions were removed, and 1 ml of ice-cold
KBB was added to the slices. The tissue was disrupted by four passages through
a 26-gauge needle; samples were centrifuged at 10,000 x g for 10 min at 4°C,
and the supernatant fractions were removed from the sedimented membranes.
For analyzing the DAT phosphorylation, the sedimented membranes were
solubilized with 0.5% SDS sample buffer (60 mM Tris pH 6.9, 0.5% SDS, 10%
Glycerol. 100 mM DTT) at 50 mg/ml original wet weight. The samples were
centrifuged at 20,000 x g for 30 min to remove the insoluble material and soluble
fraction was used for immunoprecipitation with DAT antibody 16 followed by
SDS-PAGE and autoradiography. For in situ proteolysis sedimented membranes
were resuspended in 50 mM Tris-HCI, pH 8.0, at 50 mg/ml original wet weight.
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[3 H] DA Uptake Assay
Dopamine uptake assays were performed in rDAT expressing LLC-PK^
cells. Cells were washed twice with 1 ml of Krebs-Ringer HEPES (KRH) buffer
(25 mM HEPES, 125 mM NaCI, 4.8 mM KCI, 1.2 mM KH2 P04, 1.3 mM CaCI2,
1.2 mM MgS04, 5.6 mM glucose, pH 7.4). Triplicate wells were pretreated at
37°C for 30 min or other indicated times with 1 ml KRH containing vehicle, DA,
drugs, BIM, or PMA prior to assay for transport. Test compounds (DA, (-)cocaine, (3-CFT, mazindol, MPH) were prepared in deionized water, GBR 12909
was solubilized in ethanol and diluted with buffer, and PMA and BIM were
prepared at high concentration in DMSO followed by dilution to a final DMSO
concentration of 01-0.5%. For these initial experiments, saturating
concentrations of uptake biockers were used. At the end of the prcireatments,
cells were placed on ice to minimize potential reversal of treatment effects and
rapidly washed three times with 1 mi ice-cold KRH to remove the drugs prior to
assay for DA transport. Uptake was initiated by adding 10 pi of a 100* DA stock
solution to bring the final concentrations of [3 H] DA to 10 nM and total DA to
3 pM. 100 pM (-)-cocaine was used to determine Non-specific uptake and was
subtracted from total uptake values to obtain the specific uptake. Uptake assays
were carried out at 37°C for

8

min and terminated by rapidly washing the wells

three times with 1 ml ice-cold KRH. Cells were solubilized in 500 pi of RIPA
buffer consisting of 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS,
150 mM NaCI, 10 mM sodium phosphate, 2 mM EDTA, 50 mM sodium fluoride,
0.2 mM sodium vanadate, 1 pM okadaic acid and one Complete Mini® Protease
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Inhibitor Cocktail. Lysates were measured for incorporated radioactivity using a
Packard 1900CA liquid scintillation counter at 62% efficiency.
Photoaffinity Labeling
Wild type rDAT expressing LLC-PKt cells were split into 6 well plates and
were grown to 90-95% of confluence. Cells were washed twice with ice-cold KRH
buffer and incubated with 5nM [ 1 2 5 l] RTI82 radioactive ligand, cocaine analogue
on ice for 1h. Following the incubation, the lid of petri-dish was removed and the
cells were exposed to UV light (254 nm) for 45 sec. Cells were washed with icecold KRH two times and solubilized with 500pl of RIPA containing Complete
Mini® Protease Inhibitor Cocktail. The cell lysate was centrifuged at 20,000 * g
for 30 min at 4°C. The soluble fraction extract was immunoprecipitated and used
as a control for metabolic phosphorylation experiments.
Recombinant Cloning of Cytosolic Tails of DAT
Fusion protein expression plasmids pTYB2 or pTYB12 obtained from NEB
were used to clone and express DAT cytosolic tail fusion proteins in E.coli.
These plasmids allowed fusion of tag consisting of the intein and the chitin
binding domain (CBD), to either the C-terminus (pTYB2) or the N-terminus
(pTYB12) of the target protein. In the presence of thiols, such as DTT, the intein
undergoes specific self-cleavage which releases the target protein from the
chitin-bound intein tag. Customized oligonucleotide primers containing restriction
sites were designed and obtained from MWG biotech to amplify the open reading
frame encoding the rat N-terminal cytosolic tail (NDAT) (amino acids 1-65) and
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C-terminal cytosolic tail (CDAT) (amino acids 579-619) domains of DAT using
PCR.
Cloning of NDAT
The open reading frame sequence of ~210 nucleotides corresponding to
NDAT were amplified from the cDNA sequence of rDAT using sense primer 5 GTCCATATGAGTAAGAGCAAATGCTCCG-3* (containing Nde I site) and
antisense primer 5 -CAGCCCGGGCTTGCTCCAGGTCTCCCGCTCT-3'
(containing Sma I site). The amplified sequence was purified and the identity of
the sequence was verified by DNA sequencing (Alpha Biolabs, CA) and was
subcloned into pTYB2 plasmid that produces an N-terminal tag to NDAT after
expression. 2 pg of amplified PCR product or 250 ng of pTYB1 plasmid was
subjected to sequential double digestion, first with 10U of Sma I at 25°C for 3 h
and then with 10U of Nde i at 37°C in NEB buffer 4 overnight. After completion of
the reaction, the pTYB2 plasmid mixture was dephosphorylated using 5U of
Antarctic phosphatase (NEB) at 37°C to prevent the recircularization of the
plasmid. The reaction products of both samples were purified using Min-Elute
purification kit and eluted into DNase free water. Ligation was performed by
adding 1:3 molar ratios of linearized pTYB2 plasmid and PCR product to the
ligation reaction mixture consisting of ligation buffer and 10U of T4 DNA ligase at
16°C overnight. Nova Blue™ (Novagen) competent cells were transformed with 2
pi of ligation reaction mix and were grown on LB agar petri-dishes containing 100
pg/ml of carbenecillin overnight at 37°C to screen for recombinant plasmid. The
putative colonies were randomly selected and regrown in LB medium overnight
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to prepare plasmids as described below. The integration of insert and identity of
the sequence of the purified plasmid was verified by DNA sequencing. The
recombinant plasmid (NDAT-pTYB1) was used to transform the T7 express® E.
coli cells (NEB) to express the fusion protein.
Cloning of CDAT
The open reading frame sequence of ~135 nucleotides corresponding to
CDAT were amplified from the cDNA sequence of rDAT using sense primer 5'GTACAGAATGCTTTCTGCAGCCTGCCGGGGT-3’ (Bsm I) and antisense
primer 5 -GGGCCCCTCGAGTTACAGCAACAGCCAGTGACGC-3’ (Xho I). The
amplified product was purified and the identity of the sequence was verified by
DNA sequencing (Alpha Biolabs, CA) and was subcloned into pTYB12 plasmid
that produces a C-terminal tag to CDAT after expression 2 pg of amplified PCR
product or 250 ng of pTYB12 plasmid was subjected to sequential double
digestion, first with 20U of Bsm I at 65°C for 4h and then with 10U of Xho I at
37°C in NEB buffer 2 and 100 pg/ml of BSA overnight. After completion of the
reaction, pTYB12 plasmid mixture was dephosphorylated using 5U of Antarctic
phosphatase (NEB) at 37°C to prevent the recircularization of the plasmid. The
reaction products of both samples were purified using Min-Elute purification kit
and eluted into DNase free water. Ligation was performed by adding 1:10 molar
ratios of linearized pTYB12 plasmid and PCR product to the ligation reaction
mixture consisting of ligation buffer and 10U of T4 DNA ligase at 16°C overnight.
Nova Blue™ competent cells were transformed with 2 pi of ligation reaction mix
and were grown on LB agar petri-dishes containing 100 pg/ml of carbenecillin
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overnight to screen for recombinant plasmid. The putative colonies were
randomly selected and sub-cultured in LB medium overnight to prepare the
plasmid as described below. The integration of insert and the identity of the
sequence of the purified plasmids were verified by DNA sequencing. The
recombinant plasmid (CDAT-pTYB12) was used to transform the T7 express™
E. coli cells (NEB) to express the fusion protein.
Site-directed Mutagenesis
Mutant NDAT or rDAT expressing constructs containing threonine (T)
substituted to alanine (A) were produced from pTYB2-NDAT and pcDNA- rDAT
constructs using the Stratagene QuikChange& kit (La Jolla, CA). The
oligonucleotide primers utilized to mutate codons were designed by using “The
QuikChauge® Primer Design Program” (http://www.stratagene.com) and
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synthesized by MWG Biotech. The QuikChange mutagenesis reaction was
performed by sequential addition of reaction components mentioned below in
Table 1 and by PCR. The PCR parameters were programmed in a thermocycler
machine as mentioned in Table 2. Following the PCR reaction, 10U of Dpn I was
added to the reaction mix and incubated at 37°C for 1 h to digest the template
DNA. Nova Blue™ competent cells were transformed with 2 pi of reaction mix
and grown on LB agar petri-dishes containing 100 pg/ml of carbenecillin
overnight. Transformed bacterial colonies were randomly selected and sub
cultured in LB medium overnight to prepare the plasmid as described below. The
purified plasmids were sequenced for accuracy of mutagenesis (Alpha biolabs,
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CA), and were used to transform or transfect T7 express™ E.coli as described
below.
Table 1. Quick Change® Reaction Mixture
Vol (pi)
5

Reagent
10X Reaction buffer (100 mM KCI, 100 mM (N H ^S O ^ 200 mM
Tris-HCI pH8 .8 , 20 mM MgS04, 1% Triton®, 1 mg/m! nucleasefree BSA)
Template DNA (5ng/pl)
Forward oligonucleotide primer ( 125ng)
Reverse oligonucleotide primer ( 125ng)
dNTP mix
Nuclease free water
Final Volume

20

1.25
1.25
1

21.5
50

Table 2. Quick Change® Thermal Cycling Parameters
Segment

Cycles

1

1

2

16

Temperature
95°C
95°C
55°C
6 8 °C

Time
30 sec
30sec
1 min
8 min

Bacterial Transformation and Plasmid Preparation
Nova Blue™ singles (Calbiochem) and T7 express™ competent cells
(NEB) aliquots were transformed with 1-2 pi of plasmid DNA or ligation mix or
PCR mix according the standard procedures described by the manufacturer. The
LB agar petri-dish containing 100 pg/ml of carbenecillin was spread with
transformed bacterial suspension and was incubated at 37°C overnight.
Transformed bacterial colonies were randomly selected from the LB agar
petri-dish and were sub-cultured in glucose M9Y medium supplemented with 100
pg/ml of carbenecillin at 30°C in a shaking incubator at 200 rpm for > 16 h. The
bacterial cells were harvested from medium by centrifugation at 5000 * g for
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10min at 4°C. The plasmid was isolated by using Pure Yield® plasmid Midi prep
system (Promega) or GenElute u Plasmid Miniprep Kit (Sigma). The isolated
plasmid was electrophoresed on a 1% agarose gel containing 0.5 pg/ml ethidium
bromide and separated plasmids were visualized by using GrabIT annotating
grabber 2.04.6 (UVP Inc, Upland, CA). The quality and quantity of plasmid DNA
was assessed using Beckman DU 640 spectrophotometer. The following formula
was used to calculate cone, of DNA; [DNA pg/ml] = A26o (50) (dilution factor).
Expression and Purification of NDAT or CDAT
To express NDAT- CBD or CDAT-CBD intein fusion protein, E.coli 77
express™ (NEB) cells were transformed with pTYB2-NDAT or CDAT-pTYB12
respectively and colonies were selected on LB agar plate containing 50 pg/ml of
carbenecillin. The transformed bacterial colony was inoculated in LB medium
containing 50 pg/ml of carbenecillin and grown to an O.D6oo of 0 . 8 at 37°C.
Fusion protein expression was induced with 0.5 mM isopropyl p-D-1thiogalactopyranoside (IPTG) for 16 h at 16°C. The bacterial culture was
centrifuged at 5000 * g for 10 min at 4°C to harvest cells. The bacterial pellet
was resuspended with ice cold lysis buffer (50 mM Tris, 150 mM NaCI, 0.05%
Triton X-100 and one Complete Mini® protease inhibitor Cocktail tablet) and the
suspension was subjected to French press (160001b/ inch2) to prepare a crude
extract. The crude extract was centrifuged at 20,000 * g for 30 min to separate
the soluble supernatant fraction from cell debris.
The soluble fraction of lysate was passed through a 2 ml bed volume of
chitin column resin that composed of chitin coated agarose beads (NEB).
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Stringent washings v ->re performed with

20

bed volumes of column buffer (50

mM Tris, 500 mM NaCI, 1 mM EDTA) to enrich the fusion protein on column. The
target proteins NDAT or CDAT were released from fusion tags by incubating the
column with 3 bed volumes of the cleavage buffer (50 mM of DTT in column
buffer) for 40 h at 4°C. Following the incubation, the elution fractions were
collected and resolved by SDS-PAGE followed by commassie staining or
immunoblot to verify the on column cleavage of target proteins. The eluted NDAT
or CDAT fragment was dialyzed against 20 mM MOPS to remove DTT.
In Vitro Phosphorylation Assays
PKC Classical Isoforms
1.5 pg of purified NDAT or 7.5 pg of histones was incubated in a reaction
mixture consisting of 20 mM MOPS pH 7.4, DOPS (40 pg/ml), DAG ( r . 6 pg/ml), 5
mM MgCI2, 300 pM CaCI2, 40 pM ATP and 0.22 U of PKC isoforms (a, pi, pll,
and y). These reactions were initiated by adding 12 pCi of [y-3 2 P] ATP and
incubated at 30°C for 30 min. 100 mM EDTA was used to terminate reactions.
Histones were used as a positive control to test the kinase specificity.
CaMK II
1.5 pg of purified NDAT was incubated in a reaction mixture consisting of
20 mM MOPS pH 7.4, 2.4 pM calmodulin, 5 mM MgCI2, 300 pM CaCI2, 40 pM
ATP and 100 U of CaMK II. These reactions were initiated by adding 12 pCi of [y32

P] ATP and incubated at 30°C for 30 min. 100 mM EDTA was used to terminate

this reaction. Myelin basic protein was used as a positive control to test the
kinase specificity.
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PKA

1.5 |jg °f purified NDAT was incubated in a reaction mixture consisting of
20 mM MOPS pH 7.4, 5 mM MgCI2, 300 pM CaCi2, 40 pM ATP and 1250 U of
PKA. These reactions were initiated by adding 12 pCi of [y-32PJ ATP and
incubated at 30°C for 30 min. 100 mM EDTA was used to terminate the reaction.
Histones were used as a positive control to test the kinase specificity.
PKG
1.5 pg of purified NDAT was incubated in a reaction mixture consisting of
20 mM MOPS pH 7.4, 10 pM 8 -Br cGMP, 5 mM MgCI2, 300 pM CaCI2, 40 pM
ATP and 5000 U of PKG. These reactions were initiated by adding 12 pCi of fy32

P] ATP and incubated at 30°C for 30 min. 100 mM EDTA was used to terminate

the reaction. Histones were used as a positive control to test the kinase
specificity.
ERK1/2, AM, Cdk-5, p38, and GSK-3p
1.5 pg of purified NDAT or CDAT was incubated in a reaction mixture
consisting of 20 mM MOPS pH 7.4, 5 mM MgCI2, 300 pM CaCf2r 40 pM ATP and
10,000 U of GSK-3P or 100 U of activated ERK1 or ERK2. These reactions were
initiated by adding 12 pCi of [y-3 2 P] ATP and incubated at 30°C for 30 min. 100
mM EDTA was used to terminate the reactions. Myelin basic protein was used as
a positive control to test the kinase specificity.
CKII
1.5 pg of purified NDAT was incubated in a reaction mixture consisting of
20 mM MOPS pH 7.4, KCI, 5 mM MgCI2, 300 pM CaCI2, 40 pM ATP and 1000U
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casein kinase II. These reactions were initiated by adding 12 pCi cf [y~3 2 P] ATP
and incubated at 30°C for 30 min. 100 mM EDTA was used to terminate the
reactions. Calmodulin (CaM) was used as a positive control to test the tonase
specificity.
In Vitro Dephosphorylation Assays
In vitro phosphcrylated NDAT samples were subjected to
immunoprecipitation using rabbit polyclonal antibody 16 generated against rDAT
N-terminal amino acids 42-59 followed by dephosphorylation as described below
PP1 and PP2A
In vitro dephosphorylation assay was performed using immunoprecipitated
complexes in a reaction mixture consisting of 20 mM MOPS pH 74 , 200 pM
MnCI2, 5 mM DTT, 100 pM EDTA, 0.2 >o BSA and 2.5 U of protein phosphatase 1
or 0.02U of PP2A. Parallel experiments were perforr. *d with in vivo f 2P]
metabolically labeled rDAT.
PP2B
In vitro dephosphorylation assay was performed on immunoprecipitated
complexes in a reaction mixture consisting of 20 mM MOPS pH 7.4, 200 pM
MnCI2. 5 mM DTT, 0 2% BSA and 500U of PP2B at 30°C for 2 h The assays
were supplemented with 1 pM calmodulin and 1 mM CaCI2 5 min before initiating
the reaction.
Cell Surface Biotinylation
LLC-PKt cells expressing rDATs plated in 6 well plates and grown until
they attained 70-80% confluence. Cells were washed twice with KRH and treated
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with vehicle or test compounds (PMA, GBR 12909 ) at 37 C for 30 min,, then
were washed twice with ice-cold PBS containing 0.1 mM CaCt2 and 1 m y MgCI2
(PBS/Ca/Mg) and treated with EZ-Link® Sulfo-NHS-LC-Biotin (1 mg/ml in
PBS/Ca/Mg) two times on ice for 35 min each.. The reaction was quenched by
incubating the cells twice for 20 min with 1 mi of 100 mM glycine in PBS/Ca/Mg
at 4°C. Cells were washed with 1mf of PBS/Ca/Mg and lysed with RIPA buffer
containing protease inhibitor for 30 min on ice wvth constant shaking. The lysates
were centrifuged at 20.000 * g for 20 min at 4”C and equal amounts of protein
were used for affinity binding with 50 pi of 50% Immobilized Neutravidin beads
(Pierce) for 1h at room temperature to separate biotinylated and non-biotinylated
proteins. The unbound non-biotinylated fractions were collected and beads were
washed three times with RIPA buffer Biotinylated proteins were eluted from the
beads with 50 p! Laemmli sample buffer for 3 min at 95°C Samples were
subjected to SDS-PAGE, followed by transfer to PVDF membranes and
immunoblotting for DAT using a highly specific DAT monoclonal antibody {89J.
In Situ Proteolysis
Striatal membrane suspensions labeled with 32P were treated with 10
pg/ml of endoproteinase asp-N for 60 min, at 22°C Following proteolysis,
membranes were centrifuged at 10,000 * g for 10 min at 4°C and supernatants
were transferred to fresh tubes The sedimented membranes were washed with
1

ml of KBB and solubilized with 0.5% SDS sample buffer (50 mg/ml). To remove

the insoluble material, samples were centrifuged at 20000 * g for 30 min The
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soluble fraction was subjected to immunopreciprtation with DAT polyclonal
antibody 16 followed by electrophoresis and autoradiography.
Immunoprecipitation, Electrophoresis and Autoradiography
32

P0 4-Iabeled cell lysates or in vitro phosphorylated reaction mixtures

were immunoprecipitated with rabbit polyclonal antiserum 16 generated against
rDAT N-terminal amino acids 42-59 [63] For peptide blocking experiments,
diluted antiserum was preincubated with 50 pg/ml peptide 16 prior to addition of
the sample. Immunopreciprtates were eluted with Laemli sample buffer (62 5 mM
Tris-HCI, pH 6 .8 , 20% glycerol, 2% SDS, 5% p-mercaptoethanol, and 0.01%
bromophenol blue) and were electrophoresed on 4-20% or 10-20% gradient SDS
polyacrylamide gels with high or low range Rainbow molecular mass standards.
The electrophoresed gels were dried and subjected to autoradiography using-"
Kodak Biomax X-ray or Hyperfilm MP film. In all metabolic labeling experiments,
a parallel set of cells were photoaffinity labeled with the cocaine analog [I2 3 f]
RTI82 [90] and their lysates were subjected to immunoprecipitation and
electrophoresis to confirm the extraction and electrophoretic mobility o f 32P
labeled DAT. Molecular Analyst software (Bio-Rad) was used to scan and
quantify the autoradiograph regions of 100-110 kDa containing

32

PC>4 -labeled

DAT [64, 85]. Phosphorylation intensities of treated samples were expressed as
percent of the basal phosphorylation level, which was defined as 100% ± SE of
triplicate values.
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Eiectroelution and Dialysis
Phosphorylated ana immunoprecipitated striatal DATs or NDATs were
separated on 4-20% or 10-20% gradient tris-glycine gels by SDS-PAGE. The
gels were dried at 80°C and at 25psi for 4-6 h and exposed to Hyperfilm MP for
12-24 h. By comparing the autoradiographic image, the labeled bands at -80
kDa or ~7 kDa correspond to striatal DAT or NDAT respectively were excised
from gels and rehydrated with SDS-PAGE running buffer. The rehydrated gel
slices were subjected tc eiectroelution using 3.5 kDa membrane cut-off at 10 mA/
tube for 6 h. The electroelutes were dialyzed using SlideA-Lyzer™ (Pierce) 10
kDa or 2 kDa cut-off cassettes against distilled water with at least three changes
over 24 h. The diaiysate was concentrated to -100 pi and subjected to acetone
precipitation of proteins.

—
Acetone Precipitation of Proteins

Three-four volumes of -20°C stored acetone was added to phosphorylated
rDATs or NDATs followed by thorough mixing. The samples were stored at -20°C
for at least 2 h and then centrifuged at 15000 x g for 10 min at 4°C. The
supernatant was discarded and the protein pellets were air dried for 15 min at
room temperature. Acetone precipitated protein pellets were used for
phosphoaminoacid analysis.
Phosphoamino Acid Analysis
Phosphoamino acid analysis was performed using the method of Boyle et
at. (1991) [91]. Metabolically labeled striatal DATs or in vitro phosphorylaK '
NDAT samples were immunoprecipitated with polyclonal antiserum 16, and
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electrophoresed on 10-20% gradient gels. After drying and autoradiography, the
region of the gel containing phosphorylated striatal DAT or NDAT was excised,
and the protein was eluted in to SDS-PAGE running buffer. Eluted samples were
dialyzed against distilled water. Phosphorylated DATs or NDATs were
precipitated from dialysate using standard acetone mediated protein precipitation
procedures. The precipitated DAT or NDAT samples were acid hydrolyzed using
5.7M HCI for 1 h at 110°C. Unlabeled phosphoamino acid standards (Ser(P),
Thr(P), and Tyr(P)) (1 mg/ml) were dissolved in pH 1.9 buffer (acetic acid 7.8%,
formic acid 2.5%) at 1:15 dilution and added to the unknowns. Samples were
spotted onto cellulose thin layer plates and electrophoresed using a Hunter thin
layer electrophoresis unit at 1.5 kV for 35 min at pH 1.9 (acetic acid 7.8%, formic
acid 2.5%) in the first dimension and at 1.3 kV for 20 min at pH 3.5 (pyridine
0.5%, acetic acid 5%) in the second dimension. Standards were visualized with
ninhydrin, and the plates were subjected to autoradiography for 1-3 weeks.
Immunoblot Analysis
Cell lysates or immunoprecipitated DATs were electrophoresed on 4-20%
or 10-20% gradient Tris-glycine SDS polyacrylamide gels at 150 volts and 30 mA
for 1 h to separate the proteins. Following electrophoresis, proteins were
electrophoretically transferred to 0.45 pm polyvinylidene difluoride (PVDF)
membranes. Membranes were washed two times with distilled water and blocked
with 3% BSA prepared in 10 mM phosphate-buffered saline (PBS), pH 7 4
overnight. Membranes were probed with a highly specific DAT monoclonal
antibody diluted 1:1000 in 3% BSA, 10 mM PBS, pH 7 4 for 1 h at room
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temperature. Blots were washed 3 times with 0.1% tween, 10 mM PBS, pH 7.4
and then incubated for 1 h at room temperature with goat anti-rabbit IgG-Sinked
alkaline phosphatase conjugate diluted 1:5000 in a 3% BSA, 10 mM PBS
solution. After extensive washing, blots were developed using alkaline
phosphatase chemiluminiscent substrate Immun-Star™ (Bio-Rad) or colorimetric
substrate 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium
(NBT/BCIP) for 5-15 min. Colorimetrically developed blots were dried, scanned
and quantified with Molecular Analyst software (Bio-Rad). Blots developed with
chemiluminiscent substrates were visualized and images captured using a LumiImager (Mannheim Boehringer). Immunoreactive band intensities were
determined using LumiAnalyst software and data were analyzed with Prism 3
software.

~
Statistical Calculations and Graphs

Normalized phosphorylation values or [3 H] DA uptake values from multiple
experiments were averaged for statistical analysis by analysis of variance
(ANOVA) or student t-test and graphed using Prism 3.0 software (Graphpad
Software, Sandiego CA).
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C H A P T E R III

RESULTS
Effects of Uptake Blockers on DAT Phosphorylation
Cocaine and fi-CFT Treatment
To examine the effects of uptake blockers on DAT phosphorylation, rDAT
expressing LLC-PKi cells were metabolically labeled with 32P and treated with
vehicle or 1 pM PMA in the presence or absence of 10 pM (-)-cocaine.

32

P0 4

incorporated DATs were immunoprecipitated and analysed by SDS-PAGE
followed by autoradiography (Figure. 5, left). The cells treated with vehicle
displayed a basal level of constitutive phosphorylation on DATs (100 ± 3%) that
is defined as

10 0

% for comparison with the phosphorylation levels obtained

under experimental conditions. Phosphorylation was stimulated to approximately
two-fold by PMA (215 ± 9% of basal, p < 0.001), as previously reported [64, 85].
The addition of cocaine during the 30 min vehicle or PMA treatment had no
discernable effect on the level of either constitutive phosphorylation (98 ± 12% of
basal; p > 0.05 relative to basal) or PMA-stimulated DAT phosphorylation (177 ±
24% of basal; p < 0.01 relative to basal, p > 0.05 relative to PMA). As similar set
of studies were performed using high affinity cocaine analog p-CFT and the
results are shown in Figure. 5, right. In these experiments PMA stimulated DAT
phosphorylation levels were 184 ± 22% of basal (p < 0.01 relative to basal), while
1 pM {3-CFT alone had no effect on constitutive
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Figure 5. Cocaine and p-CFT Do not Affect Basal or PMA-Stimulated DAT
Phosphorylation. rDAT LLC-PI^ cells were metabolically labeled with 32P and
treated with or without 10 pM (-)-cocaine, 1 pM P-CFT or 1 pM PMA as indicated
for 30 min followed by immunoprecipitation, SDS-PAGE and autoradiography of
DAT. Upper panel: autoradiographs of representative experiments; lanes
correspond to treatments indicated directly below on histogram. Lower panel:
summary of DAT phosphorylation levels relative to basal (means ± SE of four
independent experiments for cocaine and three independent experiments for PCFT, performed in triplicate). *p < 0.05 relative to basal; **p < 0.01 relative to
basal;

< 0.001 relative to basal; ANOVA
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Figure 5. Cocaine and P-CFT Do not Affect Basal or PMA-Stimulated DAT
Phosphorylation.
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51

phosphorylation (100 ± 10%, p > 0.05 relative to basal) or PMA-stimulated
phosphorylation (174 ± 21% of basal; p < 0.05 relative to basal, p > 0.05 relative
to PMA).
Shorter PMA treatment times were performed using the same
combinations of drug and PMA treatments for 5 and 10 min (Figure. 6 ) to
determine if cocaine effects are transient. In these experiments PMA-stimulated
DAT phosphorylation to 178 ± 9% and 284 ± 33% of basal by 5 and 10 min
respectively (p < 0.05 and p < 0.001 relative to basal). Addition of cocaine during
5 or 10 min vehicle or PMA treatments did not show any difference in the levels
of constitutive phosphorylation (99 ± 8 % and 108 ± 8 % of basal, both p > 0.05
relative to basal) or PMA-stimulated phosphorylation respectively (210 ± 36%
and 301 ± 25% of basal at 5 min and 10 min, p < 0.01 and p < 0.001 relative to
basal; both p > 0.05 relative to matching PMA treatment time).
Mazindol, MPH or GBR 12909 Treatments
We then extended the above studies to different classes of DA uptake
blockers by examining the effects of mazindol, MPH, and GBR 12909. Mazindol
(Mazanor®) is a drug used clinically to treat obesity, which has been classified as
an appetite suppressant and has beer, shown to exhibit similar behavioral and
pharmacological effects as cocaine. Dells treated with Mazindol produced a
similar DAT phosphorylation profile as cocaine produced in this study. In these
experiments constitutive and PMA stimulated phosphorylation values were 100 ±
5% and 257 ± 34%, respectively (PMA value p < 0.01 relative to basal). The
addition of 1 pM mazindol did not affect constitutive phosphorylation
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Figure 6 . Cocaine Does not Affect Basal or PMA-Stimulated DAT
Phosphorylation at Shorter Time Points. rDAT LLC-PK1 cells were metabolically
labeled with 32P and treated with or without 10 pM (-)-cocaine or 1 pM PMA for 5
or 10 min as indicated, followed by immonoprecipitation, SDS-PAGE and
autoradiography of DAT. DAT phosphorylation levels were quantified by
densitometry and results shown are the means ± SE of two independent
experiments performed in triplicate. *p < 0.05 relative to basal; **p < 0.01 relative
to basal; ***p < 0.001 relative to basal; ANOVA.
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Figure 7 Mazindol and Methyfphenidate Do no! Affect Basai or PMA-Stmnulated
DAT Phosphorylation. rDAT LLC-PKTcells were metabolicalSy labeled with 32P
and treated with or without 1 pM mazindol (left) or 10 pM MPH (right) in the
presence or absence of 1 pM PMA for 30 min followed by immunoprecipitation,
SDS-PA6 E and autoradiography of DAT. Upper panels: autoradiographs of “
representative experiments; lanes correspond to treatments indicated directly
below on histogram Lower panel: summary of DAT phosphorylation levels
relative to basal (means ± SE of three independent experiments for both
compounds, performed in triplicate). *p < 0.05 relative to basal; **p < 0.01
relative to basal: ANOVA.
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(85 ± 14% of basal; p > 0.05 relative to basal) or PMA-stimulated phosphorylation
(279 ± 49% of basal, p < 0.01 relative to basal, p > 0.05 relative to PMA) (Figure.
7, left).
MPH (Ritalin®), a clinical drug used in the treatment of ADHD did not
affect basal or PMA-stimulated DAT phosphorylation (Figure. 7t right) like
cocaine, (3-CFT and mazindol The constitutive and PMA stimulated values were
100 ± 7% and 275 ± 48% of basal, respectively (PMA p < 0.05 relative to basal).
Inclusion of 10 pM MPH had no effect on the constitutive phosphorylation (109 ±
15% of basal; p > 0.05 relative to basal), and PMA stimulated phosphorylation
(253 ± 40% of basal; p < 0.05 relative to basal; p > 0.05 relative to PMA).
Treatment of cells with GBR 12909, a selective inhibitor for DA uptake
displayed a different phosphorylation profile. The phosphorylation intensities of
constitutive and PMA-stimulated samples were 101 ± 6 % and 186 ± 7% of basal,
respectively (PMA value p < 0.001 relative to basal). The treatment of 1 pM GBR
12909 had no effect on constitutive phosphorylation (111 ± 9% of basal, p > 0.05
relative to basal), but suppressed the PMA stimulated phosphorylation by up to
50% (147 ± 5% of basal; p < 0.001 relative to basal, p < 0.01 relative to PMA)
(Figure

8

).
Effects of Uptake Blockers on DA Transport
Cocaine Treatment

Uptake blockers were used to examine their ability to affect transport
activity or modulate PMA-stimulated DA transport down regulation. Drugs were
added to cells in combination with vehicle or PMA and incubated for 30 min at
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Figure 8 . GBR 12909 Suppresses PMA-Stimulated DAT Phosphorylation. rDAT
LLC- PKi cells were metabolicaliy labeled with 32P and treated with or without
1 pM GBR 12909 or 1 pM PMA for 30 min followed by immunoprecipitation,
SDS-PAGE and autoradiography of DAT. Upper panel: autoradiograph of
iepresentative experiment; lanes correspond to treatments indicateirdirectly
below on histogram. Lower panel: summary of DAT phosphorylation levels
relative to basal (means ± SE of three independent experiments, performed in
triplicate). ***p < 0.001 relative to basal; **p < 0.01 relative to PMA; ANOVA.
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Figure 8 . GBR 12909 Suppresses PMA-Stimulated DAT Phosphorylation.
Goreniia, B.K. and R.A. Vaughan. Neuropharmacology, 2005 49(6):p. 759-68.
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37°C. Tc remove the test compounds, cells were washed thoroughly and
subjected to [3 H] DA uptake. The [3 H] DA uptake obtained with vehicle treatment
is considered the control which is defined as

100

% and is used to normalize the

DA uptake values of other treatments. Pretreatment of cells with vehicle or
cocaine did not affect the DA transport activity or PMA-induced transport down
regulation (Figure 9A, top). The cells treated with 1 pM PMA decreased the DA
transport values to 67 ± 3% of control (p < 0.001) resulting in PMA induced down
regulation. Cells pretreated with 10 pM cocaine or cocaine plus PMA did not
affect either control transport activity (96 ± 5% of control, p > 0.05 relative to
control), or PMA induced down regulation

(68

± 3%, p < 0.001 relative to control;

p > 0.05 relative to PMA).
MPH or Mazindol Treatment
DA uptake assays were extended to study the effect of MPH and mazindol
on DA transport activity or PMA induced transport down regulation in a similar
manner as cocaine treatments. The cells pretreated with MPH do not show a
difference from control transport activity (93 ± 2% of control, p > 0 05 relative to
control) (Figure 9B). The uptake values of PMA-induced down regulation (62 ±
3% of control; p < 0 001 relative to control), were not different from a combination
treatment with MPH and PMA (63 ± 4% of control; p < 0.001 relative to control, p
> 0.05 relative to PMA). MPH pretreatment did not influence transport activity or
PMA induced transport down regulation
Mazindol pretreatment decreased the subsequent [3 H] DA uptake even
after extensive washings (78 ± 2% of control; p < 0.001 relative to control)
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Figure 9. Effects of Cocaine, Methylphenidate and Mazindol on DA Transport
Activity and PMA-Induced Down-Regulation of DA Transport Activity. rDAT LLCPKi cells were treated as indicated with (A), vehicle, 1 pM PMA or 10 pM
cocaine, (B). vehicle, 1 pM PMA or 10 pM MPH, or (C). vehicle, 1 pM PMA or
1 pM mazindol for 30 min followed by washing to remove drugs and assay for
[3 H]DA transport. Results shown are means ± SE of three independent
experiments for cocaine and two independent experiments for MPH and
mazindol, performed in triplicate. **p < 0 . 0 1 relative to control; ***p < 0 . 0 0 1
relative to control, #p < 0.05 relative to PMA, ®®®p < 0.001 relative to mazindol;
ANOVA.
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Figure 9. Effects of Cocaine, Methylphenidate and Mazindol on DA Transport
Activity and PMA-Induced Down-Regulation of DA Transport Activity.
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(Figure. 9C). To study this decrease in uptake values, we performed [3HJ CFT
ligand binding assays (not shown). Binding assays showed a 30% loss in [3 H]
CFT binding suggesting that the decrease of [3 H] DA uptake may be due to the
presence of residual drug in the cell preparation. PMA treatment showed
transport down regulation to 72 ± 4% of control (p < 0.001 relative to control), but
co-treatment with mazindol further decreased the PMA-induced transport down
regulation (56 ± 2% of control; p < 0.001 relative to control, p < 0.05 relative to
PMA, p < 0.001 relative to mazindol). This increase in PMA-induced transport
down regulation could be due to presence of residual drug that also decreased
[3 H] CFT binding. Although it is possible that this decreased f3 H] DA uptake may
also be due to the modulation of transport physiology by mazindol, our results
show that mazindol does not subvert the effects of PMA.
GBR 12909 Blocks the Internalization of DAT
In an attempt to study the effect of GBR 12909 on DA transport activity we
performed [3 H] DA uptake assays. Lack of binding reversibility of GBR 12909
following washings resulted in 10% or less DA uptake values compared to
control. In this experiment, [3 H] DA uptake was minimal because of irreversible
binding of GBR 12909, so we examined if this drug affects the cell surface
distribution of DAT by using cell surface biotinylation. The control represents the
amount of surface DAT on cells during vehicle treatment and is defined as 100%
to compare with other treatments. Treatment of cells with PMA decreased the
surface DAT levels to 67 ± 2% of control (p < 0.05) (Figure 10) suggesting that
DAT undergoes internalization and these values are comparable with previous
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Figure 10. GBR 12909 Blocks PMA-Induced DAT Internalization. rDAT LLC-PKi
cells were treated with the indicated combinations of vehicle, 10 pM PMA and
10 pM GBR 12909 for 30 min followed by cell surface biotinylation and
separation of biotinylated and non-biotinylated proteins. (A) Representative DAT
immunoblot from the biotinylated fraction of cell lysates. (B) Summary of
biotinylation levels (means ± SE of three independent experiments). *p < 0.05
relative to control; **p < 0.01 relative to control; ANOVA.
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surface DAT

Figure 10. GBR 12909 Blocks PMA-Induced DAT Internalization.
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studies. The co-treatment of GBR 12909 and PMA increased the surface
expression of DAT suggesting that GBR 12909 blocks the PMA induced
internalization of DAT. GBR 12909 treatment increased the surface expression of
DAT to 130 ± 8 % of the control (p < 0.01). These results provide preliminary
evidence that binding of GBR 12909 can affect DAT phosphorylation and DAT
endocytosis.
Effect of DA on DAT Phosphorylation
We have investigated the effects of DA on DAT phosphorylation by
treating 32P labeled cells with DA in the presence or absence of PMA (Figure
11). Addition of 10 pM DA did not affect DAT constitutive phosphorylation (90 ±
8

% of basal, p > 0.05 relative to basal) or PMA stimulated phosphorylation (PMA

value 198 ± 18% of basal, p < 0.01 relative to basal; PMA plus DA value 233 ±
28% of basal, p < 0.001 relative to basal, p > 0.05 relative to PMA). In contrast.
DAT substrates AMPH or METH induce DAT phosphorylation (85] and 5-HT or
other SERT substrates suppress PMA-induced SERT phosphorylation [92].
Effects of DA on DA Transport
DAT has been shown to undergo functional transport down regulation with
the pretreatment of DA in both synaptosomes and rDAT expressing HEK celts
[81]. However, treatment of Madine-Darby canine kidney ceils (MDCK) [93] with
DA did not affect normal DA transport activity. Here we examined if rDAT
expressing LLC-PKt cells undergo DA-induced down regulation. The cells
pretreated with 1-10 pM DA showed transport down regulation in a dose
dependent manner up to 30-40% (Figure 12A). We have also verified that PMA-
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Figure 11. DA Does not Affect Basai or PMA-Stimutated DAT Phosphorylation
rDAT LLC-PKi cells were metabolically labeled with 32 PO« and treated with or
without 10 pM DA or 1 pM PMA for 30 min, followed by immuncprecipitation,
SDS-PAGE and autoradiography of DAT. upper panel: autoradiograph of a
representative experiment, lanes correspond to treatments are indicated directly
below the histogram. Lower panel: summary of Da T phosphorylation levels
relative to basal (means ± SE of two independent experiments, performed in
triplicate). *p < 0.05 relative to basal; **p < 0.01 relative to basal; ***p < 0 001
relative to basal; ANOVA.
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Figure 11 DA Does not Affect Basal or PMA-Stimulated DAT Phosphorylation
Gorentla, B.K. and R A. Vaughan. Neurophannnacology, 2005 49(6):p 759-68.

Figure 12. DA and PMA Dose Response Curves for DA Transport DownRegulation. rDAT LLC-PKt ceils were treated with the indicated doses of DA (A)
or PMA (B), or (C). 10 pM DA with or without 10 pM cocaine, for 30 min followed
by washing and assay for [3 H]DA transport. Values shown are means ± SE of two
(A and B) or three (C) independent experiments performed in triplicate for each
compound, 'p < 0.05 relative to control: **p < 0.01 relative to control; ***p <
0.001, relative to control; *p < 0 05 relative to DA, ANOVA
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Figure 12. DA and PMA Dose Response Curves for DA Transport DownRegulation.
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induced transport down regulation occurs in a dose dependent manner.which
started at nanomolar concentrations (Figure 12B). We co-treated the cells with
10 pM of DA and cocaine and assayed for [3 H] DA uptake to examine if transport
is required for DA induced down regulation. Cocaine significantly attenuated the
DA induced down regulation in cells suggesting that this event requires active
transport (Figure 12C). Previous studies have demonstrated that LLC-PKi cells
express DA receptors and are known to activate the PKC dependent pathways
[94], that can lead to transport down regulation. To test this possibility, we
preincubated the cells with DA and D1 or D2 antagonists such as SCH 23390 or
sulpride to block the activation of DA receptors and subsequently assayed for
[3 H] DA uptake. The presence of DA antagonists did not block DA induced
transport down regulation (not shown) indicating that this process is not operating
through dopamine receptor signaling.
DA-Induced Transport Down-Regulation Occurs Through PKC-Dependent
Mechanisms
We examined the combined effects of DA and PMA on transport activity to
determine if they produce maximal levels of down regulation. In these
experiments, we co-treated the cells with high or intermediate concentrations of
DA and PMA. The individual pretreatments at higher concentration such as 15
pM DA or 1 pM PMA induced transport down-regulation to 76 ± 6 % or 64 ± 3%
of control, respectively (p < 0.01 and p < 0.001 relative to control) (Figure. 13A).
When cells were co-treated with DA and PMA at the above concentrations no
further decrease in transport activity was evident (61 ± 2 % of control, p < 0 . 0 0 1
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Figure 13. DA-Induced Transport Down-Regulation is not Additive with PMA and
is PKC Dependent. rDAT LLC-PKi cells were treated as indicated with (A)
vehicle, 1 pM PMA or 15 pM DA for 30 min, (B) vehicle, 0.3 nM PMA or 10 pM
DATor 30 min, or (C) vehicle or 10 pM BIM 30 min followed by vehicle or 20 pM
DA for an additional 30 min. Cells were washed to remove pretreatment drugs
followed by assay for [3 H]DA transport. Values shown are means ± SE of three
independent experiments, performed in triplicate. *p < 0.05 relative to control; **p
< 0 . 0 1 relative to control; ***p < 0 .0 0 1 , relative to control, **p < 0 . 0 1 relative to
BIM plus DA; ANOVA.
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relative to control, p > 0.05 relative to DA only or PMA only) suggesting that each
of these compounds achieved a maximal level of down regulation at this
concentration and maximal effects couid not be exceeded by the addition of the
other compound. Therefore, it is possible that cells may exert additive effects
when compounds are applied in intermediate concentrations. Cells incubated
with intermediate concentrations, i.e. 10 pM DA or 0.3 nM PMA induced transport
down regulation to sub-maximal levels (DA value, 87 ± 2% of control, p < 0.05
relative to control; PMA value, 80 ± 3% of control, p < 0.001 relative to control)
(Figure. 13B). When co-treated, at these concentrations, higher levels of down
regulation were not observed compared to individual treatments (86 ± 2% of
control, p < 0.05 relative to control, p > 0.05 relative to DA only or PMA only). So
an additive effect was not seen with co-treatment of DA and PMA even at
intermediate concentrations suggesting that these individual down regulatory
processes occur through a common mechanism.
To examine this possibility we incubated the cells with DA after PKC
inhibitor bisindoylmaleimide I (BIM) pretreatment and assayed for [3H] DA uptake
(Figure. 13C). DA uptake values with 20 pM DA or 10 pM BIM individual
treatments were 74 ± 2% of control (p < 0.001 relative to control) or 94 ± 3% of
control (p > 0.05 relative to control) respectively. When used in combination with
DA, BIM effectively blocked DA-induced down regulation (91 ± 4% of control; p >
0.05 relative to control, p > 0.05 relative to BIM, and p < 0.01 relative to DA)
suggesting that DA induced down regulation requires PKC. At a 10 pM
concentration, BIM can block the activity of PKA while also inhibiting PKC.
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However, previous results [63, 85] have shown that the treatment with the
specific PKA inhibitor H89 did not affect the DA transport activity. Therefore, it is
unlikely that inhibition of PKA by BIM accounts for blockade of DA induced down
regulation. Together these results suggest that DA induced down regulation
occurs by a PKC-dependent mechanism.
Purification and Immunochemical Characterization of NDAT
We have purified NDAT from precursor NDAT-CBD fusion protein that
was expressed in T7 express bacteria. We have used standard methods to
separate and purify NDAT from a crude lysate. Fractions of all the manipulations
during the purification process were collected and analyzed using SDS-PAGE
followed by commassie staining or immunoblot (Figure 14A). About 95% of the
expressed NDAT-CBD fusion protein was found in the soluble fraction of crude
extract (data not shown). The crude lysate from IPTG induced bacterial cultures
showed a strong protein band at 62 kDa on commassie-stained gel (Figure 14A,
lane 2, arrow a), while un-induced bacterial culture lysate did not display such a
band in the corresponding region (lane 1) suggesting IPTG induced the
expression of the fusion protein. To purify the NDAT-CBD fusion protein we
passed the IPTG induced lysate through a chitin column and followed by
stringent washes. Following washings we initiated the cleavage of NDAT-CBD
fusion protein by incubating the column with 50 mM DTT for 40 h at 4°C.
The E1 and E2 elution fractions were collected from the chitin column,
which showed a single NDAT protein band on commassie stained gel at 7 kDa
with 95% purity (lanes 5, 6, arrow b). These fractions were immunobioted with a

75

DAT-specific antibody that recognizes the N-terminal tail of DAT. Immunoblct
analysis snowed immunoreactivity at ~7 kDa in lanes 7 and 8 that is comparable
with commassie stained bands in lanes 5 and 6. Additionally, we found
immunoreactive protein bands which represent uncleaved NDAT fusion protein.
These results suggest that the expressed NDAT represents the N-terminal
cytosolic tail of DAT.
Further, we immunochemically characterized the purified NDAT by
immunoprecipitation and immunoblot analysis. NDATs were specifically
immunoprecipitated by poly clonal antibody 16B that recognizes the N-terminal
aminoacids 42-59 (lane 2, Figure 14B). The inclusion of immunizing peptide
competitively blocked the immunoprecipitation of NDAT as shown in lane 3. The
pre-immune serum did not immunoprecipitate NDAT (lane 4). These results
were consistent with the immunoprecipitation profile of full length rDAT (upper
panel, Figure 14B) suggesting that recombinantly expressed NDAT is indeed the
N-terminal tail of full length DAT. We have achieved a final yield of 2-5 mg of
NDAT per liter of culture.
Multiple Protein Kinases Directly Phosphorylate NDAT In Vitro
In an attempt to screen the protein kinase(s) that phosphorylate the Nterminus of DAT, we performed in vitro phosphorylation assays with
recombinantly expressed NDAT with various purified serine/threonine kinases.
The role of PKC has been well documented in DAT phosphorylation and
regulation [63, 95], Therefore, we first started with PKCa to determine if it is able
to phosphorylate NDAT in vitro. The in vitro phosphorylation was initiated with
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Figure 14. (A) Column Purification and SDS-PAGE Analysis of NDAT.
Expression of NDAT fusion protein was induced with 0.5 mM IPTG at 16°C for 16
h. Total E.coli crude lysate was passed through chitin affinity column to purify
NDAT-CBD fusion protein (an arrow on top left representing ‘a’). After washing
the column, NDAT (bottom left arrow showing b’) was cleaved from fusion tag on
column using buffer containing 50mM DTT. All the samples were analyzed by
SDS-PAGE followed by commassie staining (left) or immunoblot (right). Lane 1,
uninduced total lysate. Lane 2, totarfysate of cells induced with IPTG that was
used as input of the chitin column. Lane 3, column flow through. Lane 4,
represents column washing. Lanes 5-6 represents elution fractions E1 and E2.
Lanes 7-8 represents immunoblot analysis of E1 and E2 respectively.
(B) Immunochemical Characterization of NDAT: NDAT or rDAT was
immunoprecipitated with DAT poly 16 antibodies (Ab16), poly 16 antibody
preabsorbed peptide 16 (p16), or with preimmune serum (PI). The immune
complexes were analyzed by SDS-PAGE followed by western blot. Upper panel
shows the immunochemical reactivity of rDAT compared with NDAT in lower
panel.
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Figure 14. (A) Column Purification and SDS-PAGE Analysis of NDAT, (B)
Immunochemical Characterization of NDAT.
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purified PKCa and incubated for 30 men at 30°C. Reactions were terminated with
the addition of EDTA and NDATs were subjected to immunoprecipitatiors,, SD SPAGE and autoradiography or immunobiot (Figure 15). The results showed that
PKCa phosphorylates NDAT in vitro (lane 1) while the addition of EDTA
completely blocked NDAT phosphorylation suggesting that PKCa specifically
phosphorylated NDAT (lane 2). Other reactions that received only NDAT or only
PKCa did not show any phosphorylated band and represent negative controls
(lane 3t 4) to show that the NDAT preparation or the purified kinase do not
contain any contaminating proteins that may lead to misinterpretation of NDAT
phosphorylation. The presence of equal amounts of NDAT in these reactions was
demonstrated by immunobiot analysis (bottom panel)
We extended these studies to other protein kinases to detect if these
kinases phosphorylate NDAT in vitro Figure 16A shows the in vitro
phosphorylation of NDAT by PKC isoforms (a, fJI„ fill, and y), CaMK Ha, ERK1/2,
PKA, PKG, CKII and GSK-3f3. All the tested protein kinases phosphorylated
NDAT and were easily detectable with equal specific activities of these protein
kinases; however GSK-3p did not phosphorylate the NDAT. Surprisingly, ERK1/2
isoforms phosphorylated NDAT to greater extent than any other protein kinase.
These results suggest that multiple protein kinases may directly phosphorylate
the N-terminal tail of DAT in vi. o Additionally, immunobiot analysts of ERK
phosphorylated NDAT displayed a discrete upward shift in electrophoretic
mobility compared to unphosphorylated NDAT or NDATs that were
phosphorylated by other kinases (bottom panel, Figure 16A). This result
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Figure 15. PKCa Phosphorylates NDAT In Vitro. NDAT was phosphoryfated in
vitro by incubation with PKCa at 30°C for 30 min in the presence of 20 mM
MOPS, pH 7.4, buffer containing 5 mM MgCI2r 300 pM CaCI2, DOPS (40 pg/mi),
DAG (1.6 pg/mi), 40 pM ATP and 12 pCi of [y-32P] ATP. Foliowing the reaction
samples were analyzed by immunoprecipitation followed by autoradiography
(upper panel) or immunobiot (lower panel). Lane 1, represents the reaction mix
that contains NDAT and PKCa. Lane 2, sample that received EDTA. Lane 3- 4,
samples that did not receive either NDAT or PKCa.
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suggests that ERK mediated phosphorylation may promote different
conformation for NDAT.
ERKs are classified as proline-directed serine/threonine kinases, which
specifically phosphorylates on S/T that immediately precedes a proline (S/T-P)
[96, 97]. Such sites are also present in the distal region of NDAT, which are
amenable for phosphorylation by other proline directed protein kinases including
p38a kinase, JNK2, and Cdk 5. Although there is no evidence for these protein
kinases to regulate DA transport activity in vivo, it is possible that they may play a
role in N-terminal phosphorylation of DAT that is involved in DA efflux. Therefore
we tested if these protein kinase(s) are involved in NDAT phosphorylation.
Additionally we have also tested the ability of Akt1 to phosphorylate NDAT.
Varied levels of phosphorylation were achieved on NDATs when
incubated with different protein kinases of equal specific activity (Figure 16B).
The phosphorylation levels achieved on NDAT by these protein kinases were
represented as ERK = p38a kinase > JNK2 > Cdk > Aktf. Additionally, p38a
kinase and JNK2a2 phosphorylated NDATs have an electrophoretic shift on
immunoblot that matches the migration of ERK1-phosphorylated NDAT.
However, Cdk5 and Akt 1 phosphorylated NDATs did not show this shift on the
immunoblot. These results suggest that ERK1, p38 and JNK2 may share the
same phosphorylation site on NDAT
Because of the demonstrated regulatory roles of ERK1 and PKCa in DAT
phosphorylation and /or DAT function, we focused further studies on PKCa
and/or ERK.
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Figure16. Multiple Kinases Phosphorylate NDAT In Vitro. NDAT was
phosphorylated in vitro by incubating with different protein kinases (A) PKCa, pi,
pll, y, ERK1/2, CaMK II, PKA, PKG, GSK-3p, and CKII (B) ERK1, p38 kinase,
JNK2, Cdk5, anti7\kt1 at 30°C for 30 min in the presence of 20 mM MOPS, pH
7.4, buffer containing 5 mM MgCI2, 300 pM CaCi2, 40 pM ATP and 12 pCi of [y32P] ATP. Following the reaction, samples were analyzed by immunoprecipitation
followed by autoradiography (upper panel) or immunoblot (lower panel). The
lanes correspond to protein kinase treatments that are indicated directly above
the autoradiograph.
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In Vitro Dephosphorylation of NDAT
The application of protein phosphatase inhibitors in cell lines [63] or
treatment of cell homogenates with purified protein phosphatases [72] have
demonstrated the role of protein phosphatases on DAT phosphorylation and DA
transport activity. Here we attempted to dephosphorylate in vitro phosphorylated
NDATs by using in vitro dephosphorylation assays with exogenous protein
phosphatases. We initiated the in vitro dephosphorylation reaction by adding
purified protein phosphatases PP1, PP2A or PP2B to the reaction mixtures
consisting of PKCa or ERK1 phosphorylated NDATs or 32P labeled rDATs.
Following the reaction, the reaction products were separated by SDS-PAGE and
detected by autoradiography. The phosphorylation levels in control samples that
did not receive protein phosphatase were defined as 100% for comparison with
phosphorylation levels obtained following treatments. The results show that
PKCa-phosphorylated NDAT was completely or partially dephosphoryiated by
PP1 or PP2B respectively. However, PP2A was not able to dephosphorylate the
PKC phosphorylated NDAT (Figure 17B). A similar dephosphorylation profile was
found with 32P04 labeled rDAT samples suggesting that PP1 and/or PP2B may
regulate the PKC mediated phosphorylation of DAT in vivo (Figure 17A).
Treatment with PP1 displayed a significant amount of dephosphorylation in PKCa
phosphorylated NDAT (20.2 ± 9.6 % of control; p< 0.001 and p< 0.01 relative
control and PP2A respectively) and in 32P04 labeled rDAT (12.3 ± 5.7 % of
control; p< 0.001 and p< 0.05 relative control and PP2A respectively; with
treatment of PP1. PP2B was able to dephosphorylate PKCa-phosphorylated
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Figure 17. In Vitro Dephosphorylation of NDAT. (A) 32P metabolically labeled
rDAT samples or (B) PKCa or (C) ERK1 in vitro phosphorylated NDAT samples
were subjected to immunoprecipitation using rabbit polyclonal antibody 16. The
immunoprecipitated complexes subjected to dephosphorylation in a reaction
mixture consisting of 20 mM MOPS pH 7.4, 200 pM MnCI2, 5 mM DTT, 100 pM
EDTA, 0.2% BSA and PP1 or PP2A or PP2B at 30°C for 2 h. PP2B assays were
supplemented with 1 pM calmodulin and 1 mM CaCh, 5 min before initiation of
the reaction. Following the reaction, the samples were analyzed on SDS-PAGE
followed by immunoblot (upper panel) or autoradiography (middle panel). The
lanes correspond to treatments indicated directly below on histogram. Summary
of NDAT or rDAT phosphorylation levels relative to control (means ± SE of three
independent experiments). *p < 0.05 relative to control; **p < 0.01 relative to
control; ***p < 0.001 relative to control; ANOVA.
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Figure 18. Phosphoamino Acid Analysis of (A) PKC a and (B) ERK
Phosphorylated NDAT. PKC a or ERK1 phosphorylated NDATs were purified by
immunoprecipitation and gel electrophoresis. Autoradiographs displayed the
phosphorylation pattern demonstrated in Fig. 2A. DAT bands were excised,
eluted, and subjected to acid hydrolysis. Cerenkov counting of the hydrolysates
showed counts/min of 500 and 800 in the PKC a and ERK1 samples,
respectively. Aliquots of the hydrolysates were mixed with phosphoamino acid
standards, and amino acids were separated by two-dimensional electrophoresis
on thin layer cellulose plates. Plates were subjected to autoradiography, and
phosphoamino acid standards were visualized with ninhydrin (dotted circles). X,
origin; S, phosphoserine; T, phosphothreonine; Y, phosphotyrosine.
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Figure 18. Phosphoamir.o Acid Analysis of (A) PKC a and (B) ERK
Phosphorylated NDAT.
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NDAT to 50% of control (64.5 ± 18.0 % of control; p< 0.05) which is consistent
with rDAT (64.8 ± 12.3% of control; p< 0.01).
We extended these studies to examine if ERK-phosphorylated NDATs
undergo dephosphorylation. None of the tested protein phosphatases were able
to dephosphorylate ERK phosphorylated NDAT or alter the upward shift in
electrophoretic mobility (Figure 17C). Taken together, these studies suggest that
multiple protein phosphatases may regulate DAT dephosphorylation and different
sites display differential sensitivity for DAT dephosphorylation
Phosphoamino Acid Analysis of NDAT
From previous studies it is known that Ser and Thr residues are involved
in DAT phosphorylaton in vivo [65]. To identify the amino acid residues involved
in NDAT phosphorylation, we performed phosphoamino acid analysis of
phosphorylated NDATs. Following the in vitro phosphorylation of NDAT by PKCa
or ERK1, the products were purified by immunoprecipitation and gel
electrophoresis. The purified products were electro-eluted from gel pieces and
hydrolyzed in 6N HCI and the hydrolysate was electrophoresed on twodimensional thin layer plates along with phosphoamino acid standards After
electrophoresis, ninhydrin was applied to the TLC plates to identify the free
phosphoamino acid spots and the plates were exposed to film for
autoradiography. The results showed that PKCa phosphoryiates NDAT only on
Ser(s) (Figure 18, left), and ERK1 phosphoryiates exclusively on Thr(s) (Figure
18, right). The combination of these two results were consistent with the
presence of phospho-S and phospho-T in the phosphoamino acid analysis of full
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length DAT [65] suggesting that PKCa and ERK1 may directly phosphorate the
N-terminal tail of DAT in vivo on these residues.
MAPKs Phosphoryiate NDAT on T53
To further characterize the ERK phosphorylation, we mutated NDAT
Thr(s) (T43, T46, T53, and T62) individually to Ala by site directed mutagenesis
Standard procedures were used to express and purify the mutant NDATs The
purified mutant NDATs were subjected to in vitro phosphorylation and was
analyzed by SDS-PAGE followed by autoradiography. Figure 19A displays that
ERK1 did not phosphoryiate the T53A mutant NDAT. while other mutants were
phosphorylated to comparable levels as wild type NDAT. Similarly, p38 kinase
and JNK2 did not phosphoryiate the T53A mutant (not shown) suggesting that
T53 is a MAPKs phosphorylation site in vitro. Additionally, we did not observe an
upward shift in electrophoretic mobility with the T53A mutant on immuooblots as
was found with wild type and other mutants (bottom panel). Interestingly. T53 is
located in an ERK consensus recognition motif (P-X-S/T-P) suggesting that T53
is an optimal site for ERK phosphorylation in vivo. However, ERK can also
phosphoryiate at a minimal consensus sequence that contains S/T preceded by
proline (X-S/T-P). Such a minimal sequence is also present on the C-terminal
cytosolic tail of rat DAT at T593 in addition to N-terminus T53. It is also possiole
that the phosphorylation at T593 can contribute to the presence of T
phosphorylation in full length DAT [65]. To test this possibility we recombinantly
expressed rat DAT C-tenninal tail domain and examined if it undergoes ERK
mediated phosphorylation in vitro. The in vitro phosphorylation results showed
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Figure 19. (A) ERK 1 Phosphoryiates NDAT In Vitro on T53. Equal proteins cf
Wt or T to A mutant NDATs were phosphoryfated in vitro by incubating with
ERK1 at 3 0 X for 30 min in the presence of 20 mM MOPS, pH 7.4, buffer
containing 5 mM MgC2, 300 pM CaCI2r 40 pM ATP and 12 pCi of [y-^PJ ATP.
Following the reaction samples were analyzed by immunopreciprtation followed
by autoradiography (upper panel) or immunoblot (lower panel). Lane 1,
represents the reaction mixture that had NDAT and PKCa. Lane 2, sample that
received EDTA. Lane 3- 4, samples that do not receive either NDAT or PKCa.
The type of NDAT mutants are indicated directly above the autoradiograph. (B)
ERK 1 Does not Phosphorylate CDAT In Vitro. Equal amounts of NDAT or CDAT
were phosphoryiated in vitro by incubating with PKCa or ERK1 at SOX for 30
min as described in methods. Following the reaction samples were analyzed by
immunoprecipitation followed by autoradiography (upper panel) or immunoblot
(lower panel). The lanes correspond to treatment were indicated directly above
the autoradiograph.

Figure 19. (A) ERK 1 Phosphorylates NDAT In Vitro on T53. (B) ERK 1 Does not
Phosphorylate CDAT In Vitro.
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that ERK1 did not phosphorylate C-DAT (Figure 19B) suggesting ERK1 may not
phosphorylate the C terminal tail of DAT in vivo even though it has a minimal
consensus sequence.
N-terminal tail threonine(s) are involved in DAT phosphorylation in vivo
DAT contains multiple Ts on cytosolic tail domains, intracellular loops and
TMs. Our mutational analysis showed that T53 is a MAPK phosphorylation site in
vitro; however it is not known if T53 undergoes phosphorylation on full length
DAT in vivo.
Here we attempted to localize the threonine phosphorylation on native DAT using
in situ proteolysis with Asp-N followed by phosphoamino acid analysis. Asp-N
treatment was previously shown to proteolytically cleave DAT at D174 and yield
an intact 19 kDa N-tei.ninal peptide (Asp-N fragment) (89], For this experiment,
we metabolicaily labeled rat striatal tissue in presence of OA/OAG and performed
in situ protelolysis of striatal membranes with endoproteinase Asp-N as
described in the methods. Following proteolysis, we solubilized the membranes
and purified DATs and Asp-N fragments by immunoprecipitation using polyclonal
16B antibody that recognizes the DAT N-terminal cytosolic tail.
Immunoprecipitates were subjected to electrophoresis and autoradiography. AspN cleavage of DAT resulted in the production of a 19kDa phosphorylated Asp-N
fragment (Figure 20A, right) consistent with our previous studies [89].
We subjected the full length DAT and Asp-N fragment to standard
phosphoamino acid analysis followed by autoradiography. The results showed
the presence of phospho-T along with phospho-S in both the full length DAT (left)
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Figure 20. Threonine Phosphorylation was Found on the N-terminal Region of
DAT. (A) In Situ Proteolysis of DAT. Membranes from striatal slices labeled with
32P04 and treated with 10 pM OA plus 10 pM OAG were subjected to proteolysis
with 10 pg/ml of endoproteinase Asp-N for 1 h at 22°C. The membranes were
sedimented, solubilized, immunoprecipitated with poly clonal 16 antibodies, and
analyzed by electrophoresis and autoradiography on an 8-16% Tris-Tricine gel.
The arrow on the right denotes the position of immunoprecipitated
phosphopeptide fragments at ~19 kDa. (B) Phosphoamino Acid Analysis of Full
Length DAT and Asp-N Fragments. 32P metabolically labeled full length DATs or
Asp-N fragments were purified by immunoprecipitation and gel electrophoresis.
Autoradiographs displaying the phosphorylation pattern are demonstrated in Fig.
20A. DAT bands were excised, eluted, and subjected to acid hydrolysis.
Cerenkov counting of the hydrolysates showed counts/min of 250 and 100 in the
full length DAT and Asp-N fragment samples, respectively. Aliquots of the
hydrolysates were mixed with phosphoamino acid standards, and amino acids
were separated by two-dimensional electrophoresis on thin layer cellulose plates.
Plates were subjected to autoradiography, and phosphoamino acid standards
were visualized with ninhydrin (dotted circles). X, origin; S, phosphoserine; T,
phosphothreonine; Y, phosphotyrosine.
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Figure 20. Threonine Phosphorylation was Found on N-terminal Region of DAT.
(A) In Situ Proteolysis of DAT. (B) Phosphoamino Acid Analysis of Full Length
DAT and Asp-N Fragment.
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and the Asp-N fragment (right) (Figure 20B).We also performed control
experiments in parallel to verify that phospho-T was indeed coming from DAT but
not from contaminating proteins. For this experiment we subjected DATs to
immunoprecipitation with either polyclonal 16B or pre-immune serum followed by
phosphoamino acid analysis. The phosphoamino acid analysis of DATs that were
immunoprecipitated with polyclonal 16B showed the presence of phospho-S and
phospho-T, whereas pre-immune immunoprecipitated samples did not show any
phosphorylation signals (not shown). This result strongly argues that phospho-T
was coming from DAT, and not from any contaminant.
The 19 kDa Asp-N fragment representing the N-terminal cytosolic tail,
TMs 1-3, EL1, IL1 and proximal portion of EL2 contains T residues. Because
protein kinase accessible Thr(s) (T43, T46, T53, and T62) are present only on ~
the N-terminal cytosolic tail, it is very likely that phospho-T may be derived from
one of these four threonines. Collectively, these results suggests that T53 is a
putative DAT phosphorylation site in vivo.
Effects of MEK Inhibitors or MEK Mutants on DA Transport Activity
We independently investigated if ERKs can regulate DA transport activity
in cell lines by treating with pharmacological inhibitors of MEK or by transient
transfection of mutant MEK constructs.
For these studies, we inhibited MEK activity with PD98059 which
suppresses phosphorylation of ERK. We incubated rDAT-expressing LLC-PKj
cells with vehicle or PD98059 or PMA for 30 min at 37°C. Following treatments
cells were subjected to [3H] DA uptake. Treatment of cells with 50 pM PD98059
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decreased DA transport values to 63 ± 2.4% of control (p<0.001) (Figure 21 A)
that is consistent with previous studies [70]. Cells treated with 1 pM PMA showed
decreased DA transport values of 72.7 ± 2.1% of control (p<0.001) consistent
with previous findings [64], In addition we analyzed the levels of phospho-ERK in
cell lysates of this experiment using western blot analysis. Consistent with
previous reports [70], phosphorylated forms of ERK were markedly decreased
with the treatment of PD98059 compared to control (as shown in Figure 21B,
right).
Mansour et al., (1994) have shown that transient transfection of
constitutively active MEK mutant S218E-S222D (MEK-CA) resulted in increased
levels of phosphorylated p44 and p42 forms of MAPK relative to those
transfected with the wild-type mutant [98]. We examined the effects of MEK
mutants on DA transport. For these studies, we transiently transfected rDATexpressing LLC-PKt cells with His-taged wild-type MEK or MEK-CA or a kinasedead mutant K97M (MEK-KO) and incubated the cells for 36 h. One set of MEKWT transfected cells were treated with PD98059. Following transfection and/or
treatments, cells were subjected to [3H] DA uptake. We verified the success of
transfection by western blot analysis using anti-His specific antibody. Western
blot results showed that cells transfected with Wt or mutant MEKs constructs
expressed equal amount of Wt or mutant MEK protein (not shown). The cell
lysates from this experiment were analyzed for phospho-ERK levels. PhosphoERK levels (Figure 21 B, upper panel) and [3H] DA uptake values (Figure 21 B,
bottom panel) of MEK-WT or MEK-CA transfected cells were not significantly
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Figure 21. Effects of MEK Inhibitor or MEK Mutants on DA Transport Activity. (A)
rDAT LLC- Pl^ cells were treated as indicated with vehicle, 50 pM PD98059, or
1 pM PMA for 30 min followed by [3H] DA transport assay(B) rDAT LLC- PKi
cells were transfected as indicated with MEK-WT, MEK-CA, or MEK-KO and
subjected to immunoblot (upper panel) or [3H] DA transport assay (bottom pane!)
after 36 h. Uptake values shown are means ± SE of three (A) or eight bottom (B)
independent experiments, performed in triplicate. ***p <0.001 relative to control,
**p < 0.001 relative to control; ANOVA.
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Figure 21. Effects of MEK Inhibitors or MEK Mutants on DA Transport Activity.
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different from mock transfection (p>0.05 relative to control, n=8). Cells
transfected with MEK-KO showed a significant level of transport down regulation
(76.6 ± 4.5 % of control; p<0.001) compared to control, white not affecting the
phospho-ERK levels. However, the cells that were treated with MEK inhibitor
showed a decrease in transport (70.8 ± 3 % of control; p<0.00 ) and phosphoERK levels consistent with previous studies [70, 98]. In this study, phospho-ERK
levels do not show correlation wiih the type of transfected MEK constructs.
Therefore, we were not able to make a conclusion regarding the effects of ERKs
on DA transport activity in this experiment.
Effects of BDNF or MEK Inhibitor on DAT Phosphorylation
We attempted to examine if ERK activation or inhibition affects the DAT
phosphorylation. For Lhese studies, we used brain-derived growth factor (BDNF)
to activate the MAPK kinase pathway that results in the activation of ERKs. To
inhibit the activation of ERKs we used MEK inhibitor PD98059. Therefore, we
metabolically labeled rat striatal slices with 32P04and then treated with vehicle or
1 pM OA or 200ng/mg BDNF or 50pM PD98059. 32P04 incorporated DATs were
immunoprecipitated and analyzed by SDS-PAGE followed by autoradiography
(Figure. 22, left). In addition, we analyzed the levels of phospho-ERK in crude
lysates using immunoblot analysis. Tissues treated with vehicle displayed a basal
level of constitutive phosphorylation on DATs (100 ± 3.6%), while the OA
treatment leads to a 2-3 fold increase in DAT phosphorylation (264 ± 7% of
control; p<0.001) compared to vehicle as previously reported [63, 65]. Treatment
with PD98059 marginally decreased DAT phosphorylation to 83 ± 5.4 % of
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Figure 22: Effects of BDNF or MEK Inhibitor on DAT Phosphorylation. (A) Rat
striatal slices labeled with 32P04 were treated with vehicle, 10 pM OA, 50 pM
PD98059 or 200 ng/ml BDNF. followed by immunoprecipitation, SDS-PAGE, and
autoradiography (upper panel). The bottom panel represents immunoblot
analysis of crude striatal lysates for phospho-ERK (bottom panel). Equal
amounts of sample from treated and untreated tissue were subjected to
immunoprecipitation, electrophoresis, and autoradiography or immunoblot.
Molecular mass standards for all gels are shown in kDa. (B) Quantitation of DAT
phosphorylation. The data from three independent experiments are normalized,
averaged, and expressed as the ratio of 32P04 incorporation relative to the basal
sample ± S.E. ***p < 0.001 relative to control, *'p < 0.001 relative to control;
ANOVA.
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Figure 22: Effect of BDNF and MEK Inhibitor on DAT Phosphorylation
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controf and these values are statistically insignificant compared with control
(F.gure 22, left). The addition of BDNF increased basal DAT phosphorylation
levels to 126.9 ± 9.6% of control (Figure. 22,. right) (p<Q„Q1). In addition,, the
immunoblot results showed that BDNF or PD98059 treatments increased or
decreased the phospho-ERK levels respectively. These results are consistent
with previous reports [99)

CHAPTER IV
DISCUSSION
Differential Effects of DA and Psychoactive Drugs on DAT Phosphorylation and
Regulation.
This study investigated the acute effects of multiple DA uptake blockers on
basal and PKC-stimulated DAT phosphorylation and transport regulation To our
knowledge this is the first such study to examine p-CFT, maztndol. or MPH with
respect to most of these properties. Our results show that (-)-cocaine. p-CFT.
mazindol, or MPH do not affect the levels of basal and PMA stimulated DAT
phosphorylation in rDAT LLC-PKi cells, in contrast. Cowell et al (2000) have
reported that cocaine suppressed PMA stimulated phosphorylation in striatal
synaptosomes [88]. These investigators used a cocaine plus PMA treatment time
of 45 s. presenting the possibility that cocaine might affect an -:arly phase of
PMA-induced DAT phosphorylation or specific cocaine inducible processes in
brain that are not present in cell lines. If cocaine suppresses PMA-stimulated
phosphorylation only at shorter PMA treatment times, our results suggest that
these effects are transient and rapidly become masked or reversed by sustained
activation of PKC. Such a possibility is supported by the biphasic regulation of
SERT transport activity and phosphorylation by PKC with distinct effects
observed at shorter (1-5 min) and longer (3u min) PMA treatment times [100]. If
the different results of the DAT studies are related to cocaine-induced processes
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cocaine users, acute presence of drug would not directly affect these or related
activities. Radiotracer analogs of {3-CFT are widely used in clinical and
experimental in vivo imaging studies [103] image and quantify transporter
availability with positron emission tomography (PET) or single-photon emission
computed tomography (SPECT). The results of these studies indicate little
potential for cocaine-based imaging agents to directly produce effects on
subcellular location or binding capacity of DAT that might complicate image
interpretation.
We also examined the acute effects of other classes of DA uptake inhibitors that
are in current clinical and preclinica! use. Like cocaine, neither mazindol nor MPH
affected basal or PMA-stimulated DAT phosphorylation. MPH and mazindol
pretveatment were also without effect on DA transport, as previously found for
MPH [83], and MPH and possibly mazindol did not affect PMA-induced transport
down-regulation. Thus there is no evidence from in vitro studies to suggest that
these physiological processes would be acutely affected in patients using these
drugs. Both of these drugs induce self-administration and other cocaine-like
behaviors [47, 48], which may potentially relate to the similar lack of effects on
DAT phosphorylation and regulation.
We have also examined the acute effects of GBR 12909, a potent DA
noncompetitive inhibitor designed to treat cocaine abuse. GBR 12909 did not
affect basal DAT phosphorylation, but it strongly suppressed PMA-stimulated
phosphorylation and cell surface biotinylation. These results indicate that GBR
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12909 prevents PMA-induced down-regulation and may induce upregulation of
the DAT surface expression.
Although the GBR compound acts as a DA uptake blocker similar to
cocaine, the pharmacological properties of this drug are not clearly properly
understood. The basis for differentia! effects of GBR 12909 has oeen
hypothesized to involve ligand binding kinetics and/or binding sites [104, 105].
Unlike cocaine displacement, GBR compounds were not displaced due to their
higher hydrophobicity and therefore they cannot be removed from cells or
membranes in wash-out procedures. Hydrophobic partitioning of GBR in the
membrane may generate a continually available reservoir of ligand that results in
pseudo-irreversible binding to DAT and long-term blockade of DA transport
activity [53]. Such long-lasting binding to DAT may affect its phosphorylation or
endocytosis properties, which in turn may play a role in drug-induced behavior.
The suppression of PMA-stimulated phosphorylation by GBR 12909 may
be due to its non-specific effect on membranes. So GBR compounds alter the
ability of DAT to interact with kinases, phosphatases, or endocytic proteins. This
could also explain the unaffected basal phosphorylation during GBR treatment.
Increasing evidence indicates that cocaine or GBR 12909 binding sites are at
least partially distinct [104, 106]. Irreversible GBR analogs bind to DAT in
transmembrane domains 1 or 2 [90], suggesting the potential for binding to
induce a DAT conformation that affects phosphorylation of the adjacent Nterminal tail [65]. The suppression of PMA-induced phosphorylation and
endocytosis by GBR compounds suggests that this class of compounds could

108

attenuate functions controlled by PKC. GBR has been demonstrated to block
AMPH-iriduced DA efflux [88], but the potential functional significance of acute
GBR inhibition of this function is not obvious.
Further, we examined the effects of substrate DA on DAT phosphorylation
and DA transport activity. DA concentrations from 1-20 pM show significant dose
dependent down regulation in transport activity. The extent of DA-ind jced down
regulation is consistent with previous findings [81]. However DA did not affect
either basal or PMA stimulated DAT phosphorylation. In contrast,
psychostimulant substrates AMPH or METH induce DAT phosphorylation while
affecting transport down regulation [66, 85]. One caveat for absence of DA effect
on DAT phosphorylation is that a low level of phosphorylation induced by DA
treatment may be masked by the overall signal or may be missed if the samples
were dephosphorylated during processing [72]. Additional studies are needed to
clarify these issues. These results are related to the necessity for DAT
phosphorylation to permit efflux [40] and the differential ability of AMPH but not
DA to induce substrate channels in DAT [27].
Pretreatment with DA or PMA at sub-maximal or maximal concentrations
produced down-regulation responses that are not different from down regulatory
responses produced by co-treatments at respective concentrations. If these two
compounds exert their effects independently, it is expected that co-treatment of
DA and PMA will produce a much stronger additive effect. However, this did not
occur at sub-maximal and maximal concentrations suggesting that DA- or PKCinduced down regulation mechanisms occur via a common pathway. Additionally,
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blockade of DA-induced transport down regulation by BIM supports this idea and
Tiese results were consistent with AMPH or METH induced down regulatory
mechanisms [83, 85], Based on these studies, it is possible that pathways related
to substrate or PKC induced effects can merge in vivo and do not produce
additivity.
The mechanistic role of DA in the activation of PKC-dependent DAT
regulatory pathways is not known. Transport may change local ion
concentrations that may modulate kinases or phosphatases that act on transportdependent DAT conformations or affect DA transport-associated DAT-protein
interactions. A SNARE-dependent protein, Syntaxin 1 has been reported to
interact with N-terminal tails of GAT1 [78, 80] and regulate substrate-induced
down regulation, through interaction with N-terminal tails. Similar types of DAT
regulatory mechanisms have been proposed to be involved in DA induced
transport down regulation [73].
Our findings that application of DA did not result in interference of PKCinduced DAT phosphorylation or down-regulation contrast significantly with the
finding that substrates inhibit these properties of SERT [92]. Similarly GAT 1
GABA transporters show upregulation of function in the presence of substrate
[107], whereas DATs are down-regulated under comparable conditions. Thus for
SERT and GAT 1, substrates induce homeostatic mechanisms that maintain or
increase transmitter clearance, while the opposite occurs for DAT. Downregulation of DAT by DA requires concentrations that are significantly above the
transport Km, suggesting that the response occurs primarily under conditions of
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extreme transport demand. Transport-induced down-regulation of DAT may
represent a neuroprotective mechanism that functions when substrate levels are
high to limit translocation and cytoplasmic accumulation of DA and its neurotoxic
metabolites such as 6-hydroxydopamine that can activate apoptotic responses
(Luo et al., 1999). Individual variabilities in these molecular mechanisms may
thus to contribute to selective vulnerabilities to Parkinson's disease or other
dopaminergic pathologies.
Regulation of DAT and related neurotransmitter transporters is proving to
be a complex process involving multiple functions of these proteins, their
subcellular distribution, and trafficking. The results presented here further
contribute to the elucidation of these processes and indicate the potential for
therapeutic arid abused DAT drugs to exert some of their effects by modulation
of DAT phosphorylation and/or regulation of surface expression in addition to
their pharmacological actions.

Ill

MAPKs Phosphorylate the N-terminal Tail of DAT

In Vitro

in this study, we have shown that multiple protein kinases phosphorylate
NDAT and MAPKs specifically phosphorylate at T53 in
potentially be involved

in vivo

the first study to show the

vitro

which may

phosphorylation of DAT. To our knowledge, this is

in vitro

phosphorylation of a recombinantly expressed

N-terminus of DAT.
Evidence of in

vitro

phosphorylation of NDAT is consistent with the

presence of phosphorylation on the N-terminal tail of the DAT in
results of these studies are comparable with

in vivo

vivo

[65]. The

assays, which may reflect the

physiological conditions. Established studies have shown that PKC activators
such as PMA or OAG increase DAT phosphorylation in both LLC-PKi cells and
striatal slices indicating that PKC vs involved in DAT phosphorylation [63, 65].
The

in vitro

phosphorylation of NDAT by purified PKC is consistent with the idea

that PKC may directly phosphorylate DAT

in vivo.

Additionally, CaMK II, PKA, PKG, CdK5, Akt1, MAPKs including ERK1/2,
p38, and JNK2 phosphorylated NDAT indicating the potential for one or more
these kinases to phosphorylate DAT in

vivo.

However, there is no evidence to

support the role of multiple protein kinases in DAT phosphorylation

in vivo.

Treatment of synaptosomes with forskolin had no affect on DAT phosphorylation
suggesting that PKA may not be involved in DAT phosphorylation [63]. The roles
cf other protein kinases in DAT phosphorylation are not known. More in

vivo

experiments are needed to examine if multiple protein kinases are involved in
this process.
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phosphatases in vivo [72]. in contrast, none of the tested protein phosphatases
were able to dephosphorylate ERK-phosphorylated NDATs. Based on a shift in
electrophoretic mobility and resistance to phosphatase treatment it may be
presumed that ERK1 phosphorylated NDAT may have attained a different
structure that may be inaccessible for the tested protein phosphatases.
Further, the resistance of ERK-phosphorylated NDAT for
dephosphorylation may be explained by comparing with following caveat. The
proline-directed serine/threonine phosphorylation of Tau protein regulates
microtubule association by keeping the protein in a favorable cis-confirmation
that is not accessible to protein phosphatases such as PP2A [108, 109]. This
allows the protein to significantly retain phosphorylation for a greater duration by
checking spontaneous dephosphorylation. Biologically, this conformatiorrcan be
converted into a trans-conformation by peptidyl-proly! cis/trans isomerase
enzyme (Pin1), which is then susceptible to protein dephosphorylation and
accessible for protein phosphatases [108]. We speculate a similar type
conformational change may have occurred in ERK phosphorylated NDAT leading
to inaccessibility by protein phosphatases that result in resistance to
dephosphorylation. This distinct conformation and inaccessibility to protein
phosphatases may be implicated in a role for DAT-protein interactions. The
identification of interaction between PP2A and DAT [75] supports a potential
mechanistic relationship between PP2A and proline-directed threonine
phosphorylation.
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Our mutational analysis of MDAT followed by in vitro phosphorylation
showed that T53 is a MAPK phosphorylation site for NDAT in vitro. Even though
T53 is located in favored consensus recognition motif for ERK phosphorylation
(P-X-S/T-P), minimal consensus sequence is enough to phosphorylate STT
preceded by prollne (S/T-P) [110, 111]. Such sequences are present in Cterminal tail of rat DAT (T593) in addition to T53. The lack of phosphorylation of
T593 in CDAT and phosphorylation of T53 of NDAT by ERK suggests phcsphoT observed with full length DAT phosphoamino acid analysis may be from T53.
Further, to localize the T phosphorylation we proteoiyzed the fulWength
striatal DAT with endoproteinase Asp-N that specifically cleaves the peptide bond
on the N-terminal side of D residues. The predicted cleavage site for Asp-N is
D174 located on EL2 of BAT results in a 19 kDa phosphopepiide that showed
phospho-T with phosphoamino acid analysis suggesting that threonine
phosphorylation occurs on the N-terminal cytosolic tail. Further, the identification
of an in vitio phosphorylation site at T53 and localization of phospho-T in Asp-N
fragment suggests that T53 may be an in vivo phosphorylation site.
These results cannot rule out the possibility that phosphorylation may
occur in other portions of DAT. DAT contains potential phosphorylation sites or,
IL2, which are highly conserved throughout the cocaine sensitive
neurotransmitter transporters and has been shown to undergo phosphorylation in
both NET and SERT [112, 113]. SERT and NET undergo phosphorylation on
T276 and T258 respectively which are present on IL2 of these transporters. The
corresponding residue for DAT is T260 in IL2 of DAT, which is also located in a
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PKC/PKA/PKG consensus recognition motif. Based on these studies, it
ispossibls that T260 may also be involved in DAT phosphorylation.
Our independent study to assess the effect of ERKs on DA transport
activity was consistent with previous results. Moron et al (2003) have shown that
treatment of cells or synaptosomes with MEK inhibitor PD98Q59, decreased DA
transport activity and DAT surface expression [70]. The application of PD98059
showed decrease in transport activity while suppressing the activation of ERKs
suggesting that activation of ERKs regulates DA transport activity. The general
scheme of ERK activation involves three sequentially activated kinases. The
ERK family of MAPKs is activated by different kinds of stimuli including growth
factors, cytokines, and ligands of heterotrimeric G protein coupled receptors.
These diverse external stimuli activate the prott^-oncogenic small G protein, Ras
which in turn activates the protein kinase cascade that includes Raf —» MEK
(ERK kinase) — ERK [114j. Activity of ERKs is regulated by phosphorylation and
dephosphorylation. Dephosphorylated ERKs are inactive, but once activated by
MEK-mediated phosphorylation, ERKs then regulate the target proteins such as
phospholipases, transcription factors, and cytoskeletal proteins through direct
phosphorylation. Increasing evidence suggests that ERKs are also involved in
phosphorylation and regulation of membrane proteins including receptors,
channels, and connexins [115-117]. Hence, the regulation of these protein forms
the basis for controlling various processes including cell growth, morphogenesis,
synaptic plasticity, and learning.
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Therefore to evaluate the role of ERKs on DA transport activity, we
transiently transfected the LLC-PK, cells with MEK-CA or MEK-KO. The
transfection of a MEK-CA mutant should result in the activation of ERKs
constitutively even in the absence of growth factor [98], which results in
increased levels of phospho-ERK. The MEK-KO mutant is a kinase-dead mutant
and transfection with this mutant should produce a dominant negative effect in
the activation of ERKs that in turn results in decreased levels of phospho-ERK.
Transient expression of MEK-CA showed an increase in DA transport and
phospho-ERK levels in rDAT expressing HEK cells. (Moron et al 2003). However,
our results showed that there was no change in the levels of phospho-ERK
following the transient expression, which made it impossible to relate it with DA
transport in this study. The presence of inappropriate expression patterns in
phospho-ERK levels in this experiment can be speculated as cell type specific
effects and this result is not consistent with previous results [70, 98]. Further,
evidence for ERKs role in the regulation of DA transport has come from growth
factor stimulation studies. Recently, Hoover et al (2006) have shown that
application of BDNF leads to activation of ERKs and an increase in DA transport
in synaptosomes [99].
Based on NDAT phosphorylation studies, it can be speculated that ERKs
may promote DAT phosphorylation in vivo. To examine this possibility we
performed the 32P metabolic labeling of striatal slices in the presence of BDNF
and PD98059. Treatment with BDNF significantly increased basal DAT
phosphorylation and phospho-ERK levels. Additionally, the application of MEK
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inhibitor PD98059, showed a marginal decrease in basal DAT phosphorylation
and pb spho-ERK levels. The role of ERKs on DAT properties have been less
studied. Lin et al (2003) have reported that ERK inhibitors such as U0126
decreased basal DAT phosphorylation indicating that ERKs may regulate the
constitutive phosphorylation of DAT [68]. Taken together, these results suggest
that the activation of ERKs play a role in DAT phosphorylation. The marginal
effects of these compounds on DAT phosphorylation may be due to
inaccessibility of these compounds to the striatal tissues. Metabolic labeling of
synaptosomes may circumvent the observed partial effects of these compounds.
Collectively these results suggest that ERKs may play a role in DAT
phosphorylation and DAT regulation. Also these studies may increase the current
understanding of the role of DAT phosphorylation in DAT function. In vivo
verification of putative T53 phosphorylation site is highly warranted before
pursuing functional aspects of DAT. The best way to accomplish this can be
mass spectrometric analysis of native DATs.
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APPENDICES

A P P E N D IX A

Rat DAT cDNA sequence in pcuNA 3.0 is shown below, i he coding
sequence is underlined between the untranslated sequences.
Eco Rl
5 '.... giSBfiCCGCAGGAGTCAGTCGAAGAAGAAAGAAGCAGAGTTCCTTG
GGCTCCGGT CTACCCAT GAGTAAGAGCAAAT GCT CCGTGGGACCAAT GT CT
T CAGT GGTGGCCCCGGCTAAAGAGT CCAAT GCT GT GGGCCCCAG AG AGGT
GGAGCT CAT CCT GGT CAAGGAGCAGAACGGAGT GCAGCT GACCAACT CCA
CCCT CAT CAACCCGCCACAGACACCAGT GGAGGCT CAAGAGCGGGAGACC
TGGAGCAAGAAAATT GATTT CCTGCTAT CAGT CATCGGCTTT GCTGTGGACC
T GGCCAAT GTCT GGAGGTTT CCCTACCT GTGCTACAAAAAT GGTGGAGGT G
CCTT CCTGGTGCCCTACCT GCTCTT CATGGTTATT GCTGGGATGCCCCT CTT
CTACAT GGAGCT GGCTCT CGGACAGTT CAACAGAGAAGGAGCT GCT GGT GT
CT GGAAG AT CTGTCCT GTCCT GAAAGGTGTGGGCTTCACT GTTAT CCTCAT C
TCT1T CTACGT GGGCTT CTT CTACAATGTCATCATCGCAT GGGCACTGCACT
ACTT CTT CTCCTCCTT CACCAT GGACCT CCCAT GGATCCACT GCAACAACAC
CTGG AATAGCCCCAACT GCT CCGAT GCCCAT GCCAGCAACT CTAGCGACGG
CCT GGGCCT CAATGACACCTTT GGGACCACACCCGCTGCT GAGTACTTT GA
GCGT GGCGT GCT GCACCTT CACCAGAGCCGTGGCATT GATGACCT GGGCC
CT CCACGGT GGCAGCT CACAGCCT GCCTGGT GCT GGTCATT GTTCTGCT CT
ACTT CAGCCTATGGAAGGGAGTAAAGACCT CAGGGAAGGTGGTGT GGATCA
CAGCTACCATGCCCTAT GT GGT CCT CACAGCCCT GCTCCTGCGTGGAGTTA
CCCTT CCT GGAGCCAT GGAT GGCAT CAGAGCATACCT CAGTGT GGACTT CT
ACCG ACT CT GT GAGGC AT CT GTGT GGAT CGAT GCTGCCACCCAGGT GT GCT
TCTCCCTCGGCGTTGGGTTTGGAGTGCTGATTGCCTTCTCCAGTTACAATAA
ATT CACCAATAACT GCTATAG AGACGCAAT CAT CACCACCT CCATTAACT CC
CT GACAAGCTT CTCCTCTGGCTT CGTCGT CTT CTCCTT CCT GGGGTATAT GG
CACAG AAG CACAATGTGCCCAT CAGAGAT GT GGCCACAGAT GGACCT GGG
CT CAT CTT CATCAT CTAT CCT GAGGCG AT CGCCACACT CCCGCT GTCTTCTG
CCTGGGCTGCT GT CTTCTT CCTCATGCT GCT CACT CTGGGTAT CGACAGT G
CAAT GGGGGGCAT GGAGT CAGT GATCACT GGGCT CGTCGAT GAGTTCCAG
CT GCTACAT CGGCAT CG AGAGCTCTT CACT CTT GGCATT GT CCTGGCTACTT
T CCTGCT GTCTCTCTT CTGCGT CACCAACGGTGGCAT CTACGT CTT CACACT
GCT GGACCACTTTGCAGCTGGCACAT CTAT CCTCTTT GGCGTGCT CATT GAA
GCCATT GGGGTGGCCT GGTT CTACGGCGT CCAGCAATT CAGT GATGACAT C
AAGCAAAT GACAGGGCAGCGACCCAACCT GTACT GGCGGCTAT GCT GGAA
GCTGGT CAGCCCCT GCTT CCT CCT GTAT GTGGT CGTGGT CAGCATT GT GAC
CTT CAG ACCCCCACACTAT GGGGCCT ACAT CTT CCCAGACT GGGCCAAT GC
CCTGGGCT GGAT CATCGCCACAT CCT CCAT GGCCAT GGT GCCCATTT AT GC
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GACCT ACAAGTT CTGCAGCCT GCCGGGGT CCTT CCGGGAGAAACT GGCCT
AT GCCAT CACACCT GAGAAAGACCAT CAGCTAGT GGACAGAGGGGAGGT G
CGCCAATT CACGCTGCGT CACTGGCT GTT GCTGTAAAGTGGAAGGAGACAG
CTGCCAGCT GGGCCACCT CACAACAGCGGGGACAGGGAGAT CGCAAAGGA
AACCC ACG AGT CAAG AAAGGAAGG AGGGCCACTT CCATGCTT CTCCTTTGT
CGTACGGAAAAAT AAT CGAAGCAT GGGCTT CAACCTTTGACTGTTCACACCC
AAAT CATT GCCACAAAG AAGCCT CTGTCTGTGTATGGCTGTAAAAACATACA
CCT CTACACAGT GAGGT CAACAAT GTCCCT GTCCCTACT GGGT GGGAAAAC
CCTAGCT GGTAT CCT GTCCCT GCAAGGCT GACT CCCCCAT CTGT GGT CACT
Eco Rl
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A P P E N D IX B

The cloned pTYB2-NDAT sequence showing the rat DAT N-terminal
cytosolic tail cDNA sequence is shown below. Underlined sequence represents
the restriction sites, yellow highlighted sequence shows primer binding sites in
the pTYB2 plasmid and sequence in red letters represents cDNA sequence
representing the cleaved NDAT protein.
T7 universal primer
pTYB2 5 '.............. CGGGGATCTCGATCCCGCGAAATTAATACGACTCACTAT
AGGGG AATTGTGAGCGGATAACAATT CCCCT CTAG AAATAATTTT GTTTAAC
Nde I
TTTAAG AAGGAG ATATACAT AT GAGTAAGAGC AAATGCT CCGTGGGACCAAT
GTCTT CAGT GGT GGCCCCGGCT AAAGAGT CCAAT GCTGTGGGCCCCAGAG
AGGT GGAGCT CAT CCTGGT CAAGG AGCAGAACGGAGTGCAGCT GACCAAC
T CCACCCT CAT CAACCCGCCAC AGACACC AGT GGAGGCT CAAGAGCGGG A
Sma I
GACCT GGAGCAAGCCCGGGT GCTTTGCCAAGGGTACCAAT GTTTTAATGGC
GGAT GGGTCTATTGAAT GTATT GAAAACATT GAGGTTGGTAATAAGGTCATG
G G T...... 3'
Intein reverse sequencing primer
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A P P E N D IX C

The cloned pTYB12-CDAT sequence showing the rat DAT C-terminal
cytosolic tail cDNA sequence is shown below. Underlined sequence represents
the restriction sites, yellow highlighted sequence shows primer binding sites in
the pTYB12 plasmid and sequence in red letters represents cDNA sequence
representing the cleaved CDAT protein.
pTYB12 Intein Forward Primer -»(117 b p )......
Bsm I
5'... GGAT CCCAGGTTGTTGTACAGAAT GCTTT CTGCAGCCT GCCGGGGT CCT
TCCGGG AGAAACTGGCCTAT GCCAT CACACCT GAGAAAGACCAT CAGCTAG
TGGACAGAGGGGAGGT GCGCCAATT CACGCT GCGT CACTGGCTGTTGCT G
TAACTCGAGCCCGGGTG ACTGCAG...3'
Xho I
(58 bp) <—T7 Terminator Reverse Primer
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A P P E N D IX D

Primary protein sequence of NDAT and CDAT
NDAT:
MSKSKCSVGPMSSWAPAKESNAVGPREVELILVKEQNGVQLTNSTLINPPQTP
VEAQERETWSK
CDAT:
FCSLPGSFREKLAYAITPEKDHQLVDRGEVRQFTLRHWLLL
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A P P E N D IX E

Site directed mutagenesis primers
The sequences of oligonucleotide primers used for Quick Change6 site directed
mutagenesis. The substituted codons are highlighted in red.
Name

Sequence

T43A
Forward
Reverse

AACGGAGT GCAGCTGGCCAACT CCACCCT CATC
GATGAGGGTGGAGTT GGCCAGCT GCACT CCGTT

T46A
Forward
Reverse

CAGCT GACCAACT CCGCCCT CAT C.AACCCGCCA
T GGCGGGTT GAT GAGGGCGGAGTTGGTCAGCT G

T53A
Forward
Reverse

CTCAT CAACCCGCCACAGGCACCAGTGGAGGCT CAAGAG
CTCTT GAGCCT CCACT GGT GCCT GTGGCGGGTTGAT GAG

T62A
Forward
Reverse

GCTCAAGAGCGGGAGGCCTGGAGCAAGCCCGGG
CCCGGGCTT GCT CCAGGCCTCCCGCT CTTGAGC
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